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Discovery of Quinic Acid Derivatives as Oral Anti-inflammatory Agents
Abstract
Quinic acid (QA) esters found in hot water extracts of Uncaria tomentosa (a.k.a. Cat’s claw) exert antiinflammatory activity through mechanisms involving inhibition of the pro-inflammatory transcription
factor nuclear factor kappa B (NF-κB). Herein, we described the synthesis and biological testing of novel
QA derivatives. Inhibition of NF-κB was assessed using A549 (Type II alveolar epithelial-like) cells that
stably express a secreted alkaline phosphatase (SEAP) reporter driven by an NF-κB response element.
A549- NF-κB cells were stimulated with TNF-α (10 ng/mL) in the presence or absence of QA derivative for
18 hours followed by measurement of SEAP activity. Amide substitution at the carboxylic acid position
yielded potent inhibitors of NF-κB. A variety of modifications to the amide substitution were tolerated with
the N-propyl amide derivative 3 being the most potent. Compound 3 was named as KZ-41. The NF-kB
inhibitory potency (IC50) of our most active analog KZ-41 was determined to be 2.83±1.76 mM. Further
examination of the structure and activity relationship (SAR) demonstrated that acetylation of the hydroxyl
groups reduced NF-κB inhibitory activity. QA amide derivatives lacked anti-oxidant activity and were found
to be neither anti-proliferative nor cytotoxic at concentrations up to 100 mM.
The dehydroxyl QA amides 18 and 20 were synthesized to retain anti-inflammatory activity while having
enhanced resistance to microbial degradation. They showed NF-kB inhibition at concentration 1 mM. The
extent of NF-kB inhibition was close to positive control drug dexamethasone. The dehydroxyl QA amide
with a double bond 38 was also synthesized. The QA amide esters 24
24, 25
25, 29 and 33 were designed and
synthesized to retain anti-inflammatory activity with additional antioxidant properties. As expected,
compound 25 showed strong anti-oxidant activity. Furthermore, they were hydrolyzed by the microflora,
for an example, 25 was hydrolyzed into sinapic acid (SA) and 3. Both SA and 3 will not be consumed by
gut bacteria, and are easily absorbed in animal digestive tract. This was done by other researchers, and
not reported here.
To facilitate pre-clinical biopharmaceutic and pharmacokinetic (B/PK) studies of our lead QA amide
analog KZ-41, we developed and validated a novel hydrophilic interaction liquid chromatography–tandem
mass spectrometry (HILIC-MS/MS) analytical assay. An analog of KZ-41 was used as internal standard
(IS). KZ-41 and the IS were obtained by protein precipitation and separated by HILIC chromatography
using acetonitrile and water. A triple quadrupole mass spectrometer operating in the negative
electrospray ionization mode with multiple reaction monitoring was used to detect KZ-41 and IS
transitions of m/z 232 → 178 and 272 → 218 respectively. The lower limit of quantification (LLOQ) was 0.5
ng/mL in plasma. The method was validated for selectivity, linearity, accuracy and precision in rat plasma.
The ion suppression, recovery and stability of the analyte in the biological matrix were also tested. The
assay developed
is rapid, sensitive and robust enough to support preclinical B/PK studies of KZ-41.
The study was also conducted to characterize the biopharmaceutics and pre-clinical pharmacokinetics of
the lead QA amide analog, KZ-41. Rats (n=6/group) received a dose of either an i.v. or p.o. dose (10 mg/
kg) of KZ-41. Pharmacokinetic parameters were determined from concentration - time profiles by noncompartmental analysis. Bacterial stability study was conducted in cultured bacterial gluconobacter
oxydans. Plasma protein binding and metabolic stability were determined using equilibrium dialysis and
rat liver microsomes respectively. Following i.v. administration, KZ-41 demonstrated a medium clearance
(15.1±4.8 mL/min/kg), medium volume of distribution (3.3±1.1 L/kg), and a terminal half-life of 2.6±0.4
hrs. KZ-41 was rapidly absorbed with complete oral bioavailability (F≈1), which was consistent with the
fact that KZ-41 was not susceptible to degradation in bacterial and liver microsomal studies. KZ-41
binding to plasma proteins was about 30%. These studies demonstrate that KZ-41 is a potential new

orally active anti-inflammatory agent.
In summary, we have discovered a novel series of non-toxic QA amides that potently inhibit NF-κB. The
NF-kB inhibitory potency (IC50) of our most active analog KZ-41 was determined as 2.83±1.76 mM. It was
rapidly absorbed with complete oral bioavailability (F≈1). It could be a potential new orally active antiinflammatory agent. Mechanistic studies and pre-clinical efficacy studies of these newly designed
compounds in various in vitro and in vivo models are on-going by other researchers, and are not reported
in this dissertation.
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ABSTRACT
Quinic acid (QA) esters found in hot water extracts of Uncaria tomentosa (a.k.a.
Cat’s claw) exert anti-inflammatory activity through mechanisms involving inhibition of
the pro-inflammatory transcription factor nuclear factor kappa B (NF-κB). Herein, we
described the synthesis and biological testing of novel QA derivatives. Inhibition of NFκB was assessed using A549 (Type II alveolar epithelial-like) cells that stably express a
secreted alkaline phosphatase (SEAP) reporter driven by an NF-κB response element.
A549- NF-κB cells were stimulated with TNF-α (10 ng/mL) in the presence or absence of
QA derivative for 18 hours followed by measurement of SEAP activity. Amide
substitution at the carboxylic acid position yielded potent inhibitors of NF-κB. A variety
of modifications to the amide substitution were tolerated with the N-propyl amide
derivative 3 being the most potent. Compound 3 was named as KZ-41. The NF-B
inhibitory potency (IC50) of our most active analog KZ-41 was determined to be
2.83±1.76 M. Further examination of the structure and activity relationship (SAR)
demonstrated that acetylation of the hydroxyl groups reduced NF-κB inhibitory activity.
QA amide derivatives lacked anti-oxidant activity and were found to be neither antiproliferative nor cytotoxic at concentrations up to 100 M.
The dehydroxyl QA amides 18 and 20 were synthesized to retain antiinflammatory activity while having enhanced resistance to microbial degradation. They
showed NF-B inhibition at concentration 1 M. The extent of NF-B inhibition was
close to positive control drug dexamethasone. The dehydroxyl QA amide with a double
bond 38 was also synthesized. The QA amide esters 24, 25, 29 and 33 were designed and
synthesized to retain anti-inflammatory activity with additional antioxidant properties. As
expected, compound 25 showed strong anti-oxidant activity. Furthermore, they were
hydrolyzed by the microflora, for an example, 25 was hydrolyzed into sinapic acid (SA)
and 3. Both SA and 3 will not be consumed by gut bacteria, and are easily absorbed in
animal digestive tract. This was done by other researchers, and not reported here.
To facilitate pre-clinical biopharmaceutic and pharmacokinetic (B/PK) studies of
our lead QA amide analog KZ-41, we developed and validated a novel hydrophilic
interaction liquid chromatography–tandem mass spectrometry (HILIC-MS/MS)
analytical assay. An analog of KZ-41 was used as internal standard (IS). KZ-41 and the
IS were obtained by protein precipitation and separated by HILIC chromatography using
acetonitrile and water. A triple quadrupole mass spectrometer operating in the negative
electrospray ionization mode with multiple reaction monitoring was used to detect KZ-41
and IS transitions of m/z 232 → 178 and 272 → 218 respectively. The lower limit of
quantification (LLOQ) was 0.5 ng/mL in plasma. The method was validated for
selectivity, linearity, accuracy and precision in rat plasma. The ion suppression, recovery
and stability of the analyte in the biological matrix were also tested. The assay developed
is rapid, sensitive and robust enough to support preclinical B/PK studies of KZ-41.
The study was also conducted to characterize the biopharmaceutics and preclinical pharmacokinetics of the lead QA amide analog, KZ-41. Rats (n=6/group)
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received a dose of either an i.v. or p.o. dose (10 mg/kg) of KZ-41. Pharmacokinetic
parameters were determined from concentration - time profiles by non-compartmental
analysis. Bacterial stability study was conducted in cultured bacterial gluconobacter
oxydans. Plasma protein binding and metabolic stability were determined using
equilibrium dialysis and rat liver microsomes respectively. Following i.v. administration,
KZ-41 demonstrated a medium clearance (15.1±4.8 mL/min/kg), medium volume of
distribution (3.3±1.1 L/kg), and a terminal half-life of 2.6±0.4 hrs. KZ-41 was rapidly
absorbed with complete oral bioavailability (F≈1), which was consistent with the fact that
KZ-41 was not susceptible to degradation in bacterial and liver microsomal studies. KZ41 binding to plasma proteins was about 30%. These studies demonstrate that KZ-41 is a
potential new orally active anti-inflammatory agent.
In summary, we have discovered a novel series of non-toxic QA amides that
potently inhibit NF-κB. The NF-B inhibitory potency (IC50) of our most active analog
KZ-41 was determined as 2.83±1.76 M. It was rapidly absorbed with complete oral
bioavailability (F≈1). It could be a potential new orally active anti-inflammatory agent.
Mechanistic studies and pre-clinical efficacy studies of these newly designed compounds
in various in vitro and in vivo models are on-going by other researchers, and are not
reported in this dissertation.
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CHAPTER 1. INTRODUCTION
The interest in development of natural products or modified natural products
having anti-inflammatory activity has exploded in recent years. Recently, quinic acid
(QA) and QA esters have been identified as active anti-inflammatory ingredients in hot
water extracts of the herbal Uncaria tomentosa or Cat’s claw (e.g., C-MED-100),1,2
and shown to enhance immune cell response and DNA repair in humans.3-5 This chapter
will give an overview on the most recent studies on QA and its derivatives in the
following fields, such as: biosynthesis and catabolism in nature, synthesis, biological
activities, mechanisms of anti-inflammatory activity, etc.
1.1 QA Structure and Its Derivatives
QA, 1,3,4,5-Tetrahydroxy-cyclohexanecarboxylic acid (Figure 1-1), was first
reported in 1790.6 The structure and the stereochemistry of QA were assigned in 1932 by
H. O. L. Fisher and G. Dangschat.7 QA is a natural compound found widely in plants,8-10
such as in cinchona bark, particularly in South American barks; also largely in apple,
peach, and rose tissue.11,12 Derivatives of QA, such as chlorogenic acid (CGA) (Figure
1-1), p-coumaryl quinate, etc., are also common in plants.13-15
1.2 QA Biosynthesis and Catabolism
1.2.1 The QA Biosynthesis
In nature, QA could be synthesized in one step from dehydroquinate by quinate
dehydrogenase or from shikimate by quinate hydrolyase (Figure 1-2).16 Although the
accumulation of QA appears to be restricted to specific plants, the occurrence of
chlorogenate and its derivatives is more widespread. In higher plants, QA is the
precursor for chlorogenate and may also serve as a storage or transport form of carbon.17
Chlorogenate is the major soluble phenylpropanoid in tobacco and a preformed protectant
against fungal attack.18 It contributes to general plant health as part of a physical and
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Figure 1-2. QA biosynthesis and biodegradation cycle. The cycle includes three
intermediates of the shikimate pathway. DAHP: 3-deoxy-o-arabino-heptulosonate 7phosphate. EPSP: 5-enolpyruvylshikimate 3-phosphate. The enzymes of the QA cycle are
(1) quinate (shikimate) dehydrogenase (QDH); (2) 3-dehydroquinate dehydratase (DQD);
and (3) quinate hydrolyase. 3-Dehydroshikimate is aromatized to protocatechuate by
Sdehydroshikimate dehydratase (4). Bold arrows indicate reactions of the main trunk of
the shikimate pathway.
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possibly also a chemical barrier against microbial attack. Once this barrier is broken, the
constituents become potential carbon sources for the attacker.
1.2.2 The Shikimate Pathway
The QA biosynthesis and biodegradation is through the shikimate pathway. In
Figure 1-2, the bold arrows indicate reactions of the main trunk of the shikimate pathway.
There are seven enzymes that catalyze the sequential steps of the shikimate pathway. The
first reaction is catalyzed by 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase
(DAHP), phosphoenol pyruvate and erythrose-4-phosphate are reacted to form 3-deoxydarabino-heptulosonate 7-phosphate. The second to last reaction is catalyzed by 5enolpyruvylshikimate 3-phosphate synthase (EPSP), final to chorismate. The chorismate,
the final product of the main trunk of the shikimate pathway, as a substrate for a number
of anabolic sequences to primary and secondary compounds. These compounds include
the aromatic amino acids phenylalanine, tyrosine, and tryptophan.19,20 The shikimate
pathway has been found only in microorganisms and plants. Bacteria spend >90% of their
total metabolic energy on protein biosynthesis. Consequently, the bacterial shikimate
pathway serves almost exclusively to synthesize the aromatic amino acids.21,22 Under
normal growth conditions, 20% of the carbon fixed by plants flows through the shikimate
pathway.23
1.2.3 The QA Degradation
QA has three biotransformation pathways (Figure 1-2).16 One is the biosynthesis
of chlorogenate in plants. The other two pathways are in both microbe and plants. QA,
along with shikimate, is readily degraded by fungi and some bacteria, first to
protocatechuate and ultimately to succinate and acetyl-COA. QA can also be degraded to
shikimate, then follow the shikimate pathway to EPSP, and chorismate, and finally to
aromatic amino acids phenylalanine, tyrosine, and tryptophan.19,20
1.3 QA Degradation by Microorganisms
One of the remarkable features of QA and shikimate pathway is the very different
patterns of enzyme organization found in different species.24 In 1967, a QA oxidizing
enzyme produced by acetic acid bacteria was discovered demonstrating that bacteria
could catabolize QA.25 Subsequently, the QA catabolic pathway was described as a result
of characterization of fungal mutants with lesions in genes encoding biosynthetic
shikimate pathway enzymes.26 QA, along with shikimate, are degraded to form
protocatechuate. The first three steps of QA catabolism are an NAD-dependent oxidation
to form dehydroquinate, followed by two successive dehydrations to form
dehydroshikimate and protocatechuate. The enzymes responsible for these conversions
are quinate dehydrogenase (QDH), 3-dehydroquinate dehydratase (DQD), and 3dehydroshikimate dehydratase. Both QDH and DQD are located in the cytoplasmic
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membrane of bacteria. The QDH can also convert shikimic acid to dehydroshikimate.
Bacteria and fungi utilize QA as a growth substrate and thus express an abundance of the
aforementioned enzymes involved in QA degradation. High levels of QA catabolizing
enzymes in gut bacteria is consistent with the finding that less than 10% of an orally
administered dose QA is recovered in rats.27
One of the significant enzymes of QA degradation is QDH. QDH has been
purified and characterized, and been extensively studied in fields such as catabolism and
antibacterials.28,29 Adachi and coworkers reported QDH screening through several acetic
acid bacteria and other bacteria.28,30 Strong enzyme activity was found in the membrane
fraction of Gluconobacter melanogenus IFO 329, Gluconobacter oxydans IFO 3292,
Gluconobacter oxydans IFO 3244, and some strains of Acinetobacter calcoaceticus. The
following section describes the experimental procedure to prepare QDH enzyme from
Gluconobacter oxydans.
Experiments involving G. oxydans was performed as described previously.31 G.
oxydans (ATCC, Manassas, VA) was cultured in basal media consisting of glycerol, 3
grams of yeast extract, and 1 gram of polypepton in 1 liter of tap water. In order to induce
quinate dehydrogenase (QDH), quinate (2 g) was added and pH adjusted to 7.0.
Microorganisms was grown in medium (100 mL) at 30C. For cell-mass production, a
seed culture in 100 mL of medium was carried out overnight and transferred to 5 liters of
fresh medium in a table top shaker incubator and cultivated for 12 hr under aeration.
Harvested cells were suspended in medium (5 mM potassium phosphate and pH 6.5) and
centrifuged to pellet cells. Cells were stored without freezing.
Cell suspensions were prepared by homogenizing harvested cells at a ratio of 10 g
of wet cells per 10 mL of 5 mM potassium phosphate, pH 6.5. Cell suspsensions were
passed twice through a French pressure cell press. Intact cells were removed by low
speed centrifugation and the cell-free extract will be further centrifuged (68,000 x g for
90 min) to separate the membrane and cytoplasmic soluble fraction. The membrane
fraction was washed by homogenizing the precipitate in buffer and centrifugation
repeated.
1.4 Biological Activities of QA and Its Derivatives
Uncaria tomentosa commonly known as Una de Gato or Cat’s claw has been
widely used historically as a natural remedy, and it is currently present in a number of
nutritional formulations to treat a large variety of health disorders.32 Aqueous extracts
from the bark or root bark of Cat’s claw are used therapeutically in a diversity of diseases
including allergy, arthritis, chemotherapy side effects, cancer, bacterial/fungal infections,
gastrointestinal inflammation and gastric ulcers.33-37 The best known commercial
preparations of Cat’s claw are C-Med-100® and Activar AC-11®.38-40 The active
ingredients of C-MED-100® and Activar AC-11® have been attributed to QA, and QA
carboxy alkyl esters, such as CGA.1 Most recent studies have shown that CGA and QA
have anti-hepatitis B virus activity,41 anti-obesity property,42 radio-protective effects43
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and beneficial effects on cardiovascular diseases via suppressing P-selectin expression on
platelets.44 In particular, such extracts have been found to have various anti-inflammatory
effects such as inhibition of the production of the inflammatory cytokine TNF,
scavenges free radicals45 and the activation of the central transcription factor nuclear
factor κB (NF-κB).46-49 This factor regulates the expression of proinflammatory
cytokines.50 In the following two section, we will discuss the anti-inflammatory and antioxidation properties of QA and its derivatives, and mechanism of action.
1.4.1 The Anti-inflammatory Activity of QA and CGA through NF-κB Pathway
NF-B is made up of homodimeric and heterodimeric combinations of subunits
which, prior to activation, are located in the cytoplasm bound to an inhibitor, I-κB. The
biological system in which NF-B plays the most important role is the immune system.
There are many reviews available for this subject, such as Ghosh et al. in 2004 and
1998,51,52 Li and Verma in 2002,53 Bonizzi and Karin in 2004.54 Careful regulation of the
transcriptional responses to many different stimuli is crucial to the proper functioning of
the mammalian immune system. The genes regulated by NF-κB include those controlling
programmed cell death (apoptosis), cell survival, cell adhesion, proliferation, the innateand adaptive-immune responses, inflammation, the cellular-stress response and tissue
remodeling.51,55-59 Although the maintenance of appropriate levels of NF-B activity is a
critical factor in achieving normal cellular function, there are many potential applications
of inhibition/interference of the NF-κB signal pathway in the treatment of inflammatory
disease and cancer.60-63 Calzado63 has discussed NF-κB inhibitors used for the treatment
of inflammation and cancer. Great efforts have been made for the development of highly
specific NF-κB inhibitors, some of them being currently tested in phase II clinical trials.
Chlorogenic acid (3-caffeoyl-D-quinic acid; CGA) is an ester formed between
caffeic acid (CA) and QA. CGA and other polyphenolic compounds found in fruits act as
potent antioxidants. For example, CGA and CA are both capable of scavenging NO•,64 a
pro-inflammatory oxygen radical produced via the L-arginine pathway by infiltrating
leucocytes.65 Interestingly, QA does not possess antioxidant activity suggesting
alternative mechanisms underlie its anti-inflammatory activity.64 One potential
mechanism involves inhibition of NF-B. Using Jurkat T cells transfected with an NFB-dependent reporter gene, it was demonstrated that QA was able to inhibit PMA and
ionomycin-induced NF-B activity at concentrations that were neither cytotoxic nor
inhibited proliferation.2 The ability of QA to prevent degradation of IB- was shown to
be the mechanism by which it inhibited NF-B activity. Uniquely, QA did not affect the
amount of phosphorylated IB-. By comparison, the anti-oxidant pyrollidine
dithiocarbamate inhibited the phosphorylation, breakdown, and re-synthesis of IB-.
The authors did not further investigate the mechanism(s) involved in QA’s antiinflammatory potential. To our knowledge, proteasome inhibitors (e.g., bortezomib) are
the only approved drugs which inhibit NF-B without affecting phosphorylation of IB. Bortezomib binds to the chymotryptic site of the 20S b-subunit, thereby blocking the
proteasome. As a result IκB will not be degraded into small peptides. It remains bound to
the survival protein NF-κB, thereby inhibiting NF-κB action. Inactive NF-κB will keep
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the inflammatory gene from transcription and translation to pro-inflammatory molecules,
thus inhibiting inflammation. See Figure 1-3 from Vink et al.66
Recent work has demonstrated an interaction of QA derivatives with the
carbohydrate binding proteins (lectins) involved in key leukocyte-endothelial cell
interactions.67,68 Tetrasaccharide sialyl Lewis x (sLex) ligands found on leukocytes
contain sialic acid, L-fucose, and galactose which are essential for calcium-mediated
binding of sLex to the carbohydrate binding proteins E, P, and L-selectin.
Tetrasaccharide sLex exhibits a poor pharmacokinetic profile and thus cannot be
developed as a selectin inhibitor. A search for druggable sLex mimetics led to the
substitution of QA for fucose since the hydroxyl groups of QA mimic hydroxyl groups of
fucose which make key interactions with protein side chains that bind calcium.67,68
Selective QA analogs were shown to decrease leukocyte rolling in response to LPS in an
intravital microscopy mouse model and to decrease neutrophil influx in a murine
thioglycollate-induced peritonitis model.68 Others have shown that selective QA analogs
interact weakly with both P- and E-selectin using HL-60 cells.67
1.4.2 The Antioxidant Effect of QA and CGA
Antioxidant plays an important role in the prevention of human diseases. The
oxidative damages happen when the reactive oxygen species, e.g. superoxide (O2•) and
hydroxyl (HO•), attack the lipid in cell membranes, proteins and DNA to cause
membrane injury and protein and DNA modification.69 QA has been confirmed as
antioxidant, and extends its mode of action to include a basic nutritional benefit due to
the enhanced metabolism of both tryptophan and nicotinamide.70 But QA was not
showing its ability to trap free radicals by DPPH testing method.71 CGA and CA
derivatives possess radical scavenging activity. The antioxidant effects of CGA and its
derivatives might be due to three aspects: i) anti lipid-peroxidation; ii) radical scavenging;
and iii) antioxidation of low density lipoprotein.72
1.5 Bioavailability of QA and Its Derivatives
Although QA and its derivatives showed much good biological activity, including
anti-inflammatory activity; unfortunately, QA is utilized by gastrointestinal bacteria as a
carbon source for aromatic acid synthesis. Consequently, only a small fraction of QA is
absorbed after oral administration of QA. High levels of QA catabolizing enzymes in gut
bacteria is consistent with the finding that less than 10% of an orally administered dose
QA is recovered in rats.27 Our goal was to discover and develop stable QA derivatives as
orally drugs, and to study the bioavailability of QA and its derivatives.
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Figure 1-3. Proteasome inhibition affects NF-κB signal pathway. Bortezomib binds to
the chymotryptic site of the 20S b-subunit, thereby blocking the proteasome. As a result
IκB will not be degraded into small peptides. It remains bound to the survival protein NFκB, thereby inhibiting NF-κB action. Reprinted with permission. Vink, J.; Cloos, J.;
Kaspers, G. J. Proteasome inhibition as novel treatment strategy in leukaemia. Br J
Haematol 2006, 134, 253-62.
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1.5.1 Bioavailability of CGA
The bioavailability of CGA has been studied by several groups.73-76 Gonthier and
coworkers have studied the bioavailability of CGA and compared it with that of CA and
QA in rats fed diets supplemented with pure compounds for 8 days.73 They found that
CGA poorly absorbed through the small intestine, largely reached the cecum of rats
where it was hydrolyzed by the microflora, which exhibited esterase activities.77,78
Caffeic acid (CA) and QA were liberated and further metabolized.27,79 The proposed
CGA metabolism pathway is shown in Figure 1-4. Some of the microbial metabolites still
bearing a free phenolic group could act as antioxidants.80,81 A similar study has done by
Azuma and coworkers in 2000, they found CGA was difficult to be absorbed from
alimentary tract, although it could easily enter blood vessel after intraperitoneal
injection.74 Unlike CGA, CA was absorbed through digestive tract. The bioavailability of
CGA from green coffee extract in humans has also been studied.75 In this study, CGA
was defined as phenolic compounds formed by the esterification of cinnamic acids, such
as caffeic, ferulic, and p-coumaric acids, with QA. They were differentially absorbed
and/or metabolized throughout the whole gastrointestinal tract.
1.5.2 Bioavailability of QA
Lautemann in 1863 showed that QA was excreted to a large extent as hippuric
acid.82 This has been confirmed by several authors, such as Quick in 1931;83 Beer in
1951;84 Cotran in 1960.85 Adamson in 1970 reported that the aromatization of QA was
different between animal species, and gut bacteria played an important role in this
process.27 In man and some old world monkeys, oral quinic acid was extensively
aromatized (20-60%) and excreted in the urine as hippuric acid. The aromatization of oral
quinic acid was considerably suppressed when gut flora were suppressed by neomycin. In
the rat, only a small amount of hippuric acid was found in urine. QA was converted into
benzoic acid by gut flora in all species (Figure 1-4).27,73,86 In summary, bioavailability of
QA in animal is very low.
1.6 Synthesis of QA and Its Derivatives
QA total synthesis was reported by Grewe in 1954,87 and another route was
completed by Smissman in 1963.88 In 1964, Wolinsky developed a method to
stereospecifically synthesize QA.89 Recently, QA applications as a chiral template in
natural product synthesis have been rapidly growing. This highly functionalized substrate
was used to prepare natural compounds featuring cyclohexane substituted skeletons, and
it has also extended to the preparation of open chain building blocks, which could be
further transformed into optically active cyclopentane substituted skeletons and nitrogen
containing targets. A review prepared by Barco has comprehensively covered QA
chemistry literature up to the beginning of 1997.90 Many new chiral compounds have
been synthesized based on inexpensive chiral material QA. More recently, there are many
disease driven synthesis based on QA modification. Both Girard and Kaila have
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synthesized QA derivatives as sialyl lewis x -mimicking selectin inhibitors in order to
target E-selectin.67,68 Kim made analogues as influenza neuraminidase inhibitors with
potent anti-anfluenza activity.91 Sanchez-Sixto and Metaferia made compounds to kill
Mycobacterium tuberculosis.92,93 Payne designed derivatives to act as type II
dehydroquinase inhibitors.94 In 2001, Sefkow has synthesized CGA, 1-, 4-, and 5Caffeoylquinic Acid as antioxidant.95,96 Those esters have many other properties such as
antibacterial, antimutagenic, antitumor, and antiviral.97 Metaferia synthesized QA
derivatives macrolides that inhibit breast cancer cell migration in vitro.98 In summary, the
interest in development of modified natural products based on QA is high in recent years.
1.7 The Discovery of QA Derivatives as Oral Anti-inflammatory Agents
In this study, we will follow the modern drug discovery procedure to discover and
develop the QA derivatives, which possess orally active anti-inflammatory properties.
1.7.1 Drug Discovery
Drug discovery is very complicated, and is very important in human health, and
plays an important role in science and technology. The Science magazine presented
several special issues on this topic in 2000, 2004, and 2005.99-101 Driven by chemistry but
increasingly guided by pharmacology and the clinical sciences, drug research has
contributed more to the progress of medicine during the past century than any other
scientific factor. The advent of molecular biology and, in particular, of genomic sciences
is having a deep impact on drug discovery.102 In 2000, Uppenbrink predicted that drug
discovery is poised to revolutionized because of the soon-to-be-completed Human
Genome Project, combinatorial chemistry, and other scientific advances.99 This made the
introduction of target-based drug discovery, different from old physiology-based drug
discovery.102-104 In physiology-based drug discovery, drug was tested with animal. But in
target-based drug discovery, drug was tested with target. A target is usually a single gene,
gene product or molecular mechanism that has been identified on the basis of genetic
analysis or biological observations.105-107 After several years large increases in targetbased drug discovery R&D investment, there has been a steady decline in the number of
new molecules and biologicals that enter clinical development and finally reach the
market.108,109 This perceived failure of current drug discovery has generated widespread
concern, and several divergent opinions about the problem and its potential solutions.110
In 2008, Ho reported “Systems Biology: An Evolving Approach in Drug Discovery and
Development.”111 Butcher asked “Can cell systems biology rescue drug discovery?”110
Broadly defined, systems biology is the study of the interactions between components of
a biological and how these integrate to produce a phenotype. This contrasts with the
traditional approach that emphasized identification of the individual components of a
system.111
No matter what strategies to take, there is a practical approach in drug discovery
as shown in Figure 1-5. First, chemical compounds are made based on literature search,
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Figure 1-5. Current trends in drug discovery. SAR: Structure Activity Relationship; SADMET: Structure – Absorption, Distribution, Metabolism, Elimination, Toxicology;
SBDD: Structure Based Drug Discovery.
natural products, or clinical observations. Then biological activity is tested by biological
screening model. Structure activity relationship (SAR) is used to optimize the chemical
structure. Lead compounds are further tested to optimize their biopharmaceutical,
pharmacokinetic, and pharmacotoxic properties. That is structure – adsorption,
distribution, metabolism, elimination, toxicology (S-ADMET) study. Computer model is
also applied to assist structure based drug discovery (SBDD).
1.7.2 The Study Goals and Hypothesis
Our hypothesis states that it will be possible to convert QA into a derivative that
will retain potent anti-inflammatory activity and be resistant to microbial degradation.
This will ultimately provide orally active QA analogs. A major current concern with QA
is the fact that it is significantly modified by intestinal bacteria that prevent it from
showing good oral activity.
1.7.2.1 Synthesis of QA amide analogs
We initially focused on substitution at the carboxylic acid position, as previous
work has shown that modifications of the carboxylic acid position modulated interaction
of QA analogs with members of the selectin family (E- and P-selectin).67,68 These same
authors showed that the presence of a carboxylic acid functional group was necessary for
interaction with the selectins.67,68 A seriels of QA amides will be prepared, then go to
biological screening against our NF-κB activity HTS System. QA amide leads will form a
new template for anti-inflammatory agents. Further examination of the SAR and SADME will be conducted to optimize the leads. We hypothesize that further
modifications to the amide series including substitution of the 3-alcholic functional group
of QA will yield more potent analogs with enhanced resistance to microbial degradation.
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1.7.2.2 Synthesis of dehydroquinate amide analogs
We are also going to investigate to see if the OHs on the cyclohexane ring are
needed for anti-inflammatory activity. We plan to investigate the importance of the
hydroxyl groups on the cyclohexane ring by preparing the dehydroquinate amide analogs.
We hypothesize these modifications will retain anti-inflammatory activity with enhanced
resistance to microbial degradation. Because the first three steps of QA catabolism by
bacteria are to form dehydroquinate, followed by two successive dehydrations to form
dehydroshikimate and shikimate.16 We assume the bacteria degradation will not take
place when the new substrates lack of hydroxyl groups and/or having a double bond.
1.7.2.3 Synthesis of QA amide ester analogs
Based on the QA amide lead which serves as a new template for antiinflammatory agents, we are now planning to investigate to see if antioxidant groups are
added for having both anti-inflammatory and antioxidant activity. We will prepare a
serial of QA amide ester analogs with antioxidant groups such as caffeic acid, sinapic
acid. We hypothesize these modifications will retain anti-inflammatory activity with
additional antioxidant property. Furthermore, they will be hydrolyzed by the microflora,
for an example, CGA is hydrolyzed into Caffeic acid and QA.77,78 Both caffeic acid and
QA amide will not be consumed by gut bacteria, and easily be absorbed in animal
digestive tract.
1.7.2.4 QA derivatives anti-inflammatory activity
Comprehensive SAR studies will identify those functional groups which further
optimize activity and stability. Anti-inflammatory activity will be assessed using A549
cells containing an NF-B secreted alkaline phosphatase reporter. To serve this purpose,
we developed a cell-based high-throughput screening (HTS) system comprising A549
cells stably transfected with a plasmid containing a secreted alkaline phosphatase reporter
gene driven by an NF-κB response element (Figure 1-6). Upon TNF- stimulation, NFκB translocates to the nucleus and binds the κB response element causing transcriptional
activation. This activation drives production of the SEAP reporter, which can be
measured in the cell culture supernatant as a surrogate marker for NF-κB activity.
Cytotoxicity will be assessed using an MTS assay. Mechanistic studies and pre-clinical
efficacy studies of our lead molecules in various inflammatory animal models are studied
by other researchers, and will not be reported in this dissertation.
1.7.2.5 Lead compounds S-ADME study
Rapid degradation by gut flora potentially limits the oral effectiveness of current
QA preparations. The resistance to microbial degradation of QA analog lead compound
will be determined using bacterial Gluconobacter oxydans. Further biopharmaceutical
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Figure 1-6. NF-κB activity HTS System. A549 cells stably transfected with an NF-B
SEAP reporter were treated with TNF- (10 ng/mL) and QA analog (1 M) for 18 hours.
and pharmaceutics studies will also be done. These studies include microsomal stability,
metabolite identification, plasma protein binding, pharmacokinetics and bioavailability in
rat. In summary, The S-ADME study will investigate the bacterial stability, and
absorption, distribution, metabolism and elimination of lead compounds in rat after
intravenous and oral administration.
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CHAPTER 2. SYNTHESIS AND BIOLOGICAL EVALUATION OF QUINIC
ACID AMIDES*
2.1 Introduction
The woody plant Uncaria is widely dispersed in tropical regions, including
Southeast Asia, Africa, and South America. Uncaria genus plants have provided
numerous structurally diverse medicinal natural products (e.g., alkaloids, terpenes,
quinovic acid glycosides, flavonoids, and coumarins).112 The species with the most
compounds identified (50; 15 of which are reported as novel) is the Peruvian Uncaria
tomentosa commonly known as Uno de Gato or Cat’s claw. Most commercial Cat’s claw
preparations are based on oxindole alkaloid content as alkaloids represent the most
abundant class of compounds found in Uncaria.40
Hot water Cat’s claw extracts (e.g., C-Med 100) have very low alkaloid content
(<0.5%) and yet retain significant immune enhancing activity. For example, the extract
significantly accelerated recovery from doxorubicin-induced leukopenia in rats.38
Moreover, elevated leukocyte numbers were noted in humans, mice, and rats receiving
repeat doses of the extract.3,113 Enhanced leukocyte counts correlated with prolonged
lymphocyte survival, thus providing a potential mechanistic basis for the immune
enhancing properties of the extract.113 Prolonged cell survival has been linked to
enhanced DNA repair.3-5 Recently, quinic acid (QA) esters have been identified as
biologically active components in the extract.1
The mechanism by which QA and its esters exert their anti-inflammatory activity
is unclear, but appears to be related to inhibition of the pro-inflammatory transcription
factor nuclear factor kappa B (NF-B). For example, QA inhibited phorbol myristate
acetate (PMA) and ionomycin-induced NF-B activation in Jurkat T cells at
concentrations that neither induced cell death nor inhibited proliferation.2 Moreover, QA
prevented degradation of the NF-B inhibitor protein IB- without affecting levels of
the phosphorylated IB- protein.2 Base hydrolysis of the extract dramatically reduces
biological activity. For example, the lactone ester of QA (QAL) inhibits proliferation of
mitogen-stimulated mouse lymphocytes, whereas QA does not affect proliferation.2
Further, base hydrolysis of the extract dramatically reduces its anti-proliferative effect
against HL-60 and human mononuclear cells.1 Together, these data suggest the ester
derivatives of QA found in the extract comprise a significant fraction of the biological
activity.
QA is utilized by gastrointestinal bacteria as a carbon source for aromatic acid
synthesis. Consequently, only a small fraction of QA is absorbed after oral administration
of either QA or chlorogenic acid (CGA), which is a caffeic acid (CA)-containing ester of
*This chapter adapted with permission. Zeng, K.; Thompson, K.E.; Yates, C. R.; Miller,
D. D. Synthesis and biological evaluation of quinic acid derivatives as
anti-inflammatory agents. Bioorg Med Chem Lett, 2009, 19, 5458-60.
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QA.27 Our group has focused on the discovery and development of stable QA derivatives.
Toward this end, we have identified water soluble amide analogs of QA (1,3,4,5tetrahydroxy-1-cyclohexanecarboxylic acid) which possess potent anti-inflammatory
activity.
2.2 Results and Discussion
2.2.1 Synthesis of Quinic Acid Amides
Synthesis of the QA analogs was carried out using chemistry previously
described.67,68,114 The synthesis of the lactone 2 was carried out using PTSA in refluxing
benzene and DMF according to the procedure of Neelu Kaila et al. with minor revision.
The lactone was then allowed to react with N-propyl amine with acetic acid at 85C and
the resulting amide 3 was purified using flash chromatography.114 The amides 4-11, and
13 were formed by using different amines with lactone 2 in a manner similar to what was
described for compound 3. QA, 1, was treated with acetic anhydride /pyridine to give
compound 12.68 Each compound was characterized with Mass Spectroscopy, NMR, and
elemental analysis. The general synthesis of QA analogs is shown in Scheme 2-1.
We found that the N-propyl amide derivative 3 had the greatest extent of NF-B
inhibition following derivative in vitro A549 cells screening study.71 After that,
compound 3 was moved up into in vivo study, such as animal biological activity and
pharmacokinetics study. Large amount of compound 3 was needed. The above synthesis
method used flash chromatography for purification in both steps. Compound 2 is very
sticky on silica gel column, only about 4g could be collected after each column. It is
highly water soluble, can’t be purified by liquid-liquid separation to remove PTSA. The
optimized pathway to synthesis of amide 3 is shown in Scheme 2-2. The basic idea is to
make intermediates less polar, so aqueous wash and separation are possible during
compound purification. In Scheme 2-2, intermediate 14 was obtained in one step with
high yield (>80%),115 it can be purified just by liquid-liquid separation followed by
crystallization.
2.2.2 Biology Test of Quinic Acid Amides
The results of QA derivative anti-inflammatory high throughput screening are
presented in Figure 2-1. The N-propyl amide derivative (3) was found to have the
greatest extent of NF-B inhibition following derivative screening. We initially focused
on substitution at the carboxylic acid position, as previous work has shown that QA ester
derivatives have greater biological activity compared to QA.1,2 The carboxylic acid
substituent appears critical to the interaction of QA derivatives with E- and P-selectin,
key mediators of leukocyte endothelial cell interactions during inflammation.68
Interestingly, our most potent QA analog 3 demonstrates anti-inflammatory activity
despite the fact that it lacks a carboxylic acid functional group. Further examination of
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Figure 2-1. NF-B inhibition by QA and analogs using A549 cells stably transfected
with a secreted alkaline phosphatase (SEAP) reporter. NF-B activity was measured 18
hours after addition of TNF- (10 ng/mL) and either QA or synthesized derivatives (3-13;
1 M). Dexamethasone (Dex; 1 M) was used as a positive control. Data are presented as
percent (%) inhibition relative to control (ctl; TNF- alone) and represent % mean
inhibition ±standard deviation (n=3). Blank: media only.
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the SAR demonstrated that acetylation of the hydroxyl groups, which yields compound
12, leads to reduced NF-B inhibitory activity. A variety of modifications to the amide
substitution of 3 were tolerated, e.g., 9, 10 and 13, a N-isopropyl amide, but no
substitution was better than the N-propyl amide. The NF-B inhibitory potency (IC50) of
our most active analog 3 was determined as 2.83±1.76 M.
Next, we determined the anti-oxidant potential of QA derivatives using the 2, 2diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging method.116 The dietary
polyphenol CGA, an ester of QA and CA, possesses potent anti-oxidant activity, which is
attributed to the presence of CA. We thus compared the anti-oxidant potential of CGA,
CA, QA and 3 to determine if the anti-inflammatory activity of QA and 3 was attributable
to anti-oxidant activity. Ascorbic acid 6-palmitate was included as a structurally-distinct
molecule with described anti-oxidant activity. As expected, Figure 2-2 demonstrates the
anti-oxidant activity of CGA, CA, and ascorbic acid. However, QA and 3 have no such
anti-oxidant activity. The fact that QA does not possess anti-oxidant activity is consistent
with a previous report.64 Therefore, the NF-B inhibitory activity of QA derivatives is
attributed to mechanisms unrelated to anti-oxidant activity.
QA esters potently inhibit proliferation of mitogen-stimulated mouse lymphocytes
without increasing cytotoxicity.2 We thus determined the anti-proliferative potential of
QA and 3 against A549 cells using the MTS assay. Neither QA nor 3 exhibited cytotoxic
activity toward A549 cells at concentrations up to 100 M (Table 2-1). Thus, it appears
that inhibition of NF-B by QA and 3 is related not to anti-proliferative or cytotoxic
activity, but rather to a yet to be determined mechanism.
Figure 2-3 shows the activities of drugs in carrageenan induced paw edema
animal model. Positive control dexamethasone significantly reduced the volume of
swelled rat paw. QA and 3 had not demonstrated significantly effect on reducing paw
edema volume. Therefore, the anti-inflammatory activity of QA derivatives is attributed
to mechanisms different from carrageenan induced paw edema.
2.3 Conclusions
We have synthesized novel QA analogs that potently inhibit NF-B activity in
TNF-α-stimulated human alveolar Type II-like epithelial cells (A549). We have
demonstrated that the QA analogs presented in this work do not exert their activity via
anti-oxidant, cytotoxic, or carrageenan induced paw edema mechanisms. Mechanistic
studies and pre-clinical efficacy studies of our lead molecule 3 in various inflammatory
animal models are on-going.

19

Figure 2-2. Reaction kinetics of DPPH for determining antioxidant activity. Caffeic acid
(CA), chlorogenic acid (CGA), ascorbic acid (AA), QA and Compound 3 were prepared
in 50% acetone. The conventional colorimetric DPPH scavenging capacity was
determined by UV absorption measured at 515 nm. CA, CGA and AA showed strong
anti-oxidant activity, while QA and 3 had no anti-oxidant activity.
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Table 2-1. Cytotoxicity test of quinic acid analogs on A549SN cell line by MTS method.
Compound name
4
5

A549SN cell viability (C=100 M)

R1 structure
-C12H25
-C16H33

no observed toxicity
no observed toxicity

6

no observed toxicity

7
3

no observed toxicity
no observed toxicity

-C3H7

8

no observed toxicity
N

11

no observed toxicity
H
N

O
O

no observed toxicity

NH2

no observed toxicity
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2.4 Experimental
2.4.1 Chemistry
All reagents and solvents were purchased from Sigma Aldrich Chemical Co. (St.
Louis, MO), Fischer Scientific (Pittsburgh, PA), and TCI (Portland, OR), and were used
without any further purification. Thin layer chromatography (TLC) was performed on
silica gel chromatogram plates purchased from Analtech, Inc. Flash chromatography was
performed either on silica gel (60 Å, 200 -425 mesh) or on pre-packed silica gel columns
by using a Horizon HPFC system (Biotage, Charlottesville, VA). Molecular masses were
collected with electron spray ionization mass spectra (ESI-MS) on a Bruker/Hewlett
Packard Esquire LC/MS instrument. Nuclear magnetic resonance (NMR) spectra for 1H
NMR and 13C NMR were recorded on a Bruker ARX 300 instrument and/or a Varian
Inova-500 MHz instrument. The chemical shifts value (δ) are reported in parts per
million (ppm) relative to tetramethylsilane (TMS), and coupling constants (J) were
reported in hertz. Peaks are abbreviated as were indicated as follows: s, singlet; d, doublet;
t, triplet; m, multiplet. Deuterated solvents were purchased from Cambridge Isotope
Laboratories, Inc. Melting points were determined on a Fisher-Johns melting point
apparatus and are uncorrected. Elemental analyses (C, H, N) were performed by Atlantic
Microlab Inc. (Norcross, GA), and are accepted within ±0.4 of the theoretical values.
High performance liquid chromatography (HPLC) separation was performed on a
Hewlett Packard LC instrument with model 1100 system.
The following is the general procedure for the synthesis of quinic acid amides.
The synthesis of the lactone 2 was carried out using PTSA in refluxing benzene and DMF
according to the procedure of Neelu Kaila et al. with minor revision. The lactone was
then allowed to react with N-propyl amine with acetic acid at 85C and the resulting
amide 3 was purified using flash chromatography.114 The amides 4-11, and 13 were
formed by using different amines with lactone 2 in a manner similar to what was
described for compound 3. QA, 1, was treated with acetic anhydride /pyridine to give
compound 12.68 Each compound was characterized with Mass Spectroscopy, NMR, and
elemental analysis. The general synthesis of QA analogs is shown in Scheme 2-1.
1,3,4-Trihydroxy-6-oxa-bicyclo[3.2.1]octan-7-one (2). In a 200 mL roundbottom flask fitted with a stirring bar, reflux condenser, Dean-Stark trap, and argon inlet,
5 g of quinic acid (1,26 mmol) was placed and 10 mL of dry DMF was added via syringe
and the slurry stirred at room temperature. Next, benzene 60 mL and p-toluenesulfonic
acid 0.5 g were added, and the slurry was heated to reflux for 26h. Check TLC to confirm
the completion of reaction. A 1:1 mixture of EtOAc and heptane (100 mL) was added to
the cooled reaction mixture. The mixture was stirred for 1 hr at room temperature and
filtered. The collected solid was again stirred with a 1:1 mixture of EtOAc and heptane
(100 mL) for 1 hr at room temperature and filtered. Tituration was repeated one more
time with a 1:1 mixture of EtOAc and heptane (100 mL) and the precipitate collected to
give 3.5 g of Lactone 2 (78% yield). mp: 192-193C, Rf 0.25 (EtOAc); MS: [M-H]-: 171;
1
H NMR (300 MHz, DMSO)  1.72 (t, J=1.6 Hz, 1H), 1.82-1.88 (m, 1H), 2.07-2.13 (m,
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1H), 2.25 (d, J=1.1 Hz, 1H), 3.49 (ddd, J=11.4, 6.3, 5.7 Hz, 1H), 3.82 (t, J=4.5 Hz, 1H),
4.61 (t, J=5.1 Hz, 1H), 4.816 (d, J=6.0 Hz, 1H), 5.23 (d, J=4.5 Hz, 1H), 5.89 (s, 1H).
Anal. (C7H10O5) calculated: C, 48.28; H, 5.79. Found: C, 48.38; H, 5.76.
1,3,4,5-tetrahydroxy-cyclohexane-carboxylic acid propylamide (3). In a 50
mL round-bottom flask fitted with a stirring bar, reflux condenser, 0.196 g Lactone 2
(1.125 mmol), and propylamine (0.83 mL, 0.6g, 10.13 mmol) were combined, then
glacial acetic acid (0.19 mL, 0.20 g, 3.36 mmol) was added. The solution was warmed to
85C in oil bath for 30 min, at which time TLC (CHCl3 :MeOH:NH3OH =100:10:1)
indicated complete consumption of the starting lactone. Reaction mixture was purified by
flash column with same solvent as TLC. Collect product 3, 206mg (80% yield). mp: 132133C, Rf 0.03 (CHCl3 :MeOH:NH3OH =100:10:1); MS: [M-H]- =232; 1H NMR (300
MHz, DMSO)  0.81 (t, J=6.0 Hz, 3H), 1.41 (ddd, J=13.8, 7.5, 6.9 Hz, 2H) 1.66-1.83 (m,
4H), 3.02 (dd, J=6.9, 6.6 Hz, 2H), 3.22 (t, J=6.0 Hz, 1H), 3.75 (ddd, J=13.8, 9.0, 5.7 Hz,
1H), 3.94 (s, 1H), 4.69 (d, J=4.5 Hz, 1H), 4.90 (d, J=5.4 Hz, 1H), 5.19 (d, J=3.6 Hz, 1H),
5. 47 (s, 1H), 7.76 (t, J=5.4 Hz, 1H). Anal. (C10H19NO5) calculated: C, 51.49; H, 8.21; N,
6.00. Found: C, 51.57; H, 8.40; N, 6.01.
1,3,4,5-Tetrahydroxy-cyclohexanecarboxylic acid dodecylamide (4). In a 50
mL round-bottom flask fitted with a stirring bar, reflux condenser, 0.12 g Lactone 2
(0.706 mmol), and dodecylamine (1.19g, 6.42 mmol) were combined, then glacial acetic
acid (0.13 mL, 2.20 mmol) was added. The solution was warmed to 85C in oil bath for
30 min, at which time TLC (EtOAc) indicated complete consumption of the starting
lactone. Reaction mixture was purified by flash column with same solvent as TLC.
Collect product 4, 34 mg. Rf 0.15 (EtOAc); MS: [M-H]- =258; 1H NMR (300 MHz,
DMSO) 0.85 (t, J=6.0 Hz, 3H), 1.20-1.41 (20 H) 1.66-1.83 (m, 4H), 3.02 (dd, J=6.9, 6.6
Hz, 2H), 3.22 (t, J=6.0 Hz, 1H), 3.75 (ddd, J=13.8, 9.0, 5.7 Hz, 1H), 3.94 (s, 1H), 4.69 (d,
J=4.5 Hz, 1H), 4.90 (d, J=5.4 Hz, 1H), 5.19 (d, J=3.9 Hz, 1H), 5. 47 (s, 1H), 7.76 (t,
J=5.4 Hz, 1H).
1,3,4,5-Tetrahydroxy-cyclohexanecarboxylic acid hexadecylamide (5). In a
50 mL round-bottom flask fitted with a stirring bar, reflux condenser, 0.23 g Lactone 2
(1.34 mmol), and hexadecylamine (2.91g, 12.04 mmol) were combined, then glacial
acetic acid (0.24 mL, 4.01 mmol) was added. The solution was warmed to 85C in oil
bath for 60 min under argon, at which time TLC (EtOAc: MeOH=20:1) indicated
complete consumption of the starting lactone. Reaction mixture was purified by flash
column with same solvent as TLC. Collect product 5, 54 mg. Rf 0.05 (EtOAc:
MeOH=20:1); MS: [M-H]- =414; 1H NMR (300 MHz, DMSO) 0.85 (t, J=6.0 Hz, 3H),
1.20-1.41 (28 H) 1.66-1.83 (m, 4H), 3.02 (dd, J=6.9, 6.6 Hz, 2H), 3.22 (t, J=6.0 Hz, 1H),
3.75 (ddd, J=13.8, 9.0, 5.7 Hz, 1H), 3.94 (s, 1H), 4.69 (d, J=4.5 Hz, 1H), 4.90 (d, J=5.4
Hz, 1H), 5.19 (d, J=3.9 Hz, 1H), 5. 47 (s, 1H), 7.76 (t, J=5.4 Hz, 1H). Anal. (C23H45NO5)
calculated: C, 66.47; H, 10.91; N, 3.37. Found: C, 66.04; H, 10.91; N, 3.37.
1,3,4,5-Tetrahydroxy-cyclohexanecarboxylic acid benzylamide (6). In a 50
mL round-bottom flask fitted with a stirring bar, reflux condenser, 0.23 g Lactone 2 (1.34
mmol), and benzylamine (1.27g, 11.70 mmol) were combined, then glacial acetic acid
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(0.23 mL, 3.90 mmol) was added. The solution was warmed to 85C in oil bath for 45
min under argon, at which time TLC (CHCl3:MeOH:NH3OH =100:10:1) indicated
complete consumption of the starting lactone. Reaction mixture was purified by flash
column with same solvent as TLC. Collect product 6, 210 mg (80% yield). Rf 0.15
(CHCl3 :MeOH:NH3OH =100:10:1); MS: [M-H]- =280; 1H NMR (300 MHz, DMSO)
1.66-1.87 (m, 4H), 3.02 (dd, J=6.9, 6.6 Hz, 2H), 3.22 (t, J=6.0 Hz, 1H), 3.75 (ddd,
J=13.8, 9.0, 5.7 Hz, 1H), 3.96 (s, 1H), 4.27 (d, J=6.0 Hz, 1H), 4.69 (d, J=4.5 Hz, 1H),
4.90 (d, J=5.4 Hz, 1H), 5.22 (d, J=3.6 Hz, 1H), 5. 53 (s, 1H), 7.72 – 7.74 (m, 5H), 8.32 (t,
J=6.0 Hz, 1H). Anal. (C14H19NO5) calculated: C, 59.78; H, 6.81; N, 4.98. Found: C,
59.65; H, 6.77; N, 4.89.
1,3,4,5-Tetrahydroxy-cyclohexanecarboxylic acid cyclohexylamide (7). In a
50 mL round-bottom flask fitted with a stirring bar, reflux condenser, 0.20 g Lactone 2
(1.15 mmol), and cyclohexylamine (1.18 mL, 1.03g, 10.34 mmol) were combined, then
glacial acetic acid (0.23 mL, 3.90 mmol) was added. The solution was warmed to 85C in
oil bath for 90 min under argon, at which time TLC (CHCl3:MeOH:NH3OH =100:10:1)
indicated complete consumption of the starting lactone. Reaction mixture was purified by
flash column with same solvent as TLC. Collect product 7, 75 mg (25% yield). Rf 0.05
(CHCl3 :MeOH:NH3OH =100:10:1); MS: [M-H]- =272; 1H NMR (300 MHz, DMSO)
1.15-1.40 (m, 5H), 1.50 -1.80 (m, 8H), 3.22 (ddd, J=13.8, 9.0, 5.7 Hz, 1H), 3.50 (d, 1H),
3.70 - 3.80 (m, 1H), 3.93 (d, 1H), 4.68 (d, J=4.5 Hz, 1H), 4.87 (d, J=6.0 Hz, 1H), 5.18 (d,
J=3.9 Hz, 1H), 5. 50 (s, 1H), 7.40 (d, J=8.4 Hz, 1H). Anal. (C13H23NO5) calculated: C,
57.13; H, 8.48; N, 5.12. Found: C, 57.13; H, 8.48; N, 4.49.
1,3,4,5-Tetrahydroxy-cyclohexanecarboxylic acid phenylamide (8). In a 50
mL round-bottom flask fitted with a stirring bar, reflux condenser, 0.23 g Lactone 2 (1.34
mmol), and phenylamine (1.11 mL, 1.13g, 12.15 mmol) were combined, then glacial
acetic acid (0.24 mL, 4.40 mmol) was added. The solution was warmed to 85C in oil
bath for 120 min under argon, at which time TLC (CHCl3:MeOH:NH3OH =100:10:1)
indicated complete consumption of the starting lactone. Reaction mixture was purified by
flash column with same solvent as TLC. Collect product 8, 38 mg (10.1% yield). Rf 0.05
(CHCl3 :MeOH:NH3OH =100:10:1); MS: [M-H]- =266; 1H NMR (300 MHz, DMSO)
1.84 -1.95 (m, 4H), 3.24 - 3.32 (m, 1H) 3.80 - 3.86 (m, 1H), 4.04 (d, J=4.5 Hz, 1H), 4.73
- 4.76 (m, 2H), 5.35 (d, J=3.9 Hz, 1H), 5. 76 (s, 1H), 7.06 (t, J=7.5 Hz, 1H), 7.29 (t, J=7.5
Hz, 2H), 7.70 (t, J=7.5 Hz, 2H), 9.50 (s, 1H). Anal. (C13H17NO5.0.5H2O) calculated: C,
56.51; H, 6.57; N, 5.07. Found: C, 56.80; H, 6.48; N, 4.72.
2-[(1,3,4,5-Tetrahydroxy-cyclohexanecarbonyl)-amino]-ethyl-carbamic acid
tert-butyl ester (9). In a 50 mL round-bottom flask fitted with a stirring bar, reflux
condenser, 0.14 g Lactone 2 (0.82 mmol), and (2-Amino-ethyl)-carbamic acid tert-butyl
ester (1.07g, 6.24 mmol) were combined, then glacial acetic acid (0.13 mL, 2.10 mmol)
was added. The solution was warmed to 85C in oil bath for 180 min under argon, at
which time TLC (CHCl3:MeOH:NH3OH =100:10:1) indicated complete consumption of
the starting lactone. Reaction mixture was purified by flash column with same solvent as
TLC. Collect product 9, 270 mg (97% yield). Rf 0.05 (CHCl3 :MeOH:NH3OH
=100:10:1); MS: [M+Na]+ =357; 1H NMR (300 MHz, DMSO) 1.38 (s, 9H), 1.78 -1.82
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(m, 4H), 3.00 (d, J=3 Hz, 2H), 3.10 (d, J=3 Hz, 2H), 3.19 - 3.32 (m, 1H) 3.72 - 3.94 (m,
1H), 3.94 (d, J=4.5 Hz, 1H), 4.69 (d, J=4.8 Hz, 1H), 4.82 (d, J=6.0 Hz, 1H), 5.21 (d,
J=4.2 Hz, 1H), 5. 45 (s, 1H), 6.82 (t, J=5.4 Hz, 2H), 7.82 (t, J=6.0 Hz, 1H). Anal.
(C14H26N2O7. 0.33H2O) calculated: C, 49.40; H, 7.90; N, 8.23. Found: C, 49.56; H, 7.90;
N, 8.04.
1,3,4,5-Tetrahydroxy-cyclohexanecarboxylic acid (2-amino-ethyl)-amide (10).
In a 50 mL round-bottom flask fitted with a stirring bar, 0.22 g amide 9 (0.65 mmol),
then 10 mL solution (TFA : CH2Cl2=1:1) was added, stirred for 1 hr under argon.
Reaction mixture was evaporated to dry under reduced pressure. Then 10 mL 1.25 M
HCl- Methanol solution was added, stirred for 1 hr under argon. Reaction mixture was
evaporated to dry under reduced pressure. Collect product 10, 175 mg (99% yield). MS:
[M-Cl]+ =235; 1H NMR (300 MHz, DMSO) 1.73 -1.81 (m, 4H), 2.85 (dd, J=12, 6 Hz,
2H), 3.22 (dd, J=8.4, 3 Hz, 1H), 3.32 (d, 2H), 3.72 - 3.94 (m, 1H), 3.95 (d, J=4.5 Hz, 1H),
4.02 – 4.52 (4H), 7.91 (s, 3H), 8.09 (t, J=6.0 Hz, 1H). Anal. (C9H19ClN2O5. 0.5H2O)
calculated: C, 37.42; H, 7.33; Cl, 112.28; N, 9.70. Found: C, 37.42; H, 7.39.
Piperidin-1-yl-(1,3,4,5-tetrahydroxy-cyclohexyl)-methanone (11). In a 50 mL
round-bottom flask fitted with a stirring bar, reflux condenser, 0.20 g Lactone 2 (1.14
mmol), and piperidine (1.04 mL, 0.89g, 10.49 mmol) were combined, then glacial acetic
acid (0.20 mL, 3.50 mmol) was added. The solution was warmed to 85C in oil bath for
220 min under argon, at which time TLC (CHCl3:MeOH:NH3OH =100:10:1) indicated
complete consumption of the starting lactone. Reaction mixture was purified by flash
column with same solvent as TLC. Collect product 11, 135 mg (44.9% yield). Rf 0.05
(CHCl3 :MeOH:NH3OH =100:10:1); MS: [M+Na]+ =282; 1H NMR (300 MHz, DMSO)
1.57 -1.72 (m, 7H), 1.88 – 1.96 (m, 3H) 3.20 - 3.26 (m, 1H), 3.4 (m, 2H), 3.69 – 3.83 (m,
4H), 4.62 (d, J=4.5 Hz, 1H), 5.00 (d, J=4.8 Hz, 1H), 5.08 (d, J=5.4 Hz, 1H), 5. 56 (s, 1H).
Anal. (C12H21NO5. 0.33H2O) calculated: C, 54.33; H, 8.23; N, 5.28. Found: C, 54.66; H,
8.24; N, 5.30.
1,3,4,5-Tetraacetoxy-cyclohexanecarboxylic acid (12). In a 50 mL roundbottom flask fitted with a stirring bar, 1.35 g quinic qcid 1 (7.03 mmol), and 15 mL
anhydrous pyridine, were added. Cooled in an ice bath under argon, 15 mL acetic
anhydride was added dropwise, warmed to rt slowly, stirred for 24 hr at rt. The solvent
was removed under high vacuum to get yellow foam. The residue was purified by flash
column with solvent (EtOAc: Hex =1:1 v/v). Collect product 12, 2.41 g (97% yield). Rf
0.12 (EtOAc: Hex =1:1 v/v); MS: [M-H]- =359; 1H NMR (300 MHz, DMSO) 2.07 –
2.25 (m, 16H), 5.09 (m, 1H), 5.23 (m, 1H), 5.37 (m, 1H), 13.24(s, 1H). Anal. (C15H20O10)
calculated: C, 50.00; H, 5.59. Found: C, 50.61; H, 5,87.
1,3,4,5-Tetrahydroxy-cyclohexanecarboxylic acid isopropylamide (13). In a
50 mL round-bottom flask fitted with a stirring bar, reflux condenser, 0.19 g Lactone 2
(1.12 mmol), and isopropylamine (0.82 mL, 0.59g, 10.13 mmol) were combined, then
glacial acetic acid (0.20 mL, 0.20 g, 3.36 mmol) was added. The solution was warmed to
85C in oil bath for 30 min, at which time TLC (CHCl3 :MeOH:NH3OH =100:10:1)
indicated complete consumption of the starting lactone. The solvent was removed under
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reduced pressure. The residue was purified by flash column with same solvent as TLC.
Collect product 13, 170 mg (75% yield). Rf 0.03 (CHCl3 :MeOH:NH3OH =100:10:1);
MS: [M+H]+ =234; 1H NMR (300 MHz, DMSO)  1.02 (d, J=6.6 Hz, 6H), 1.61-1.78 (m,
4H), 3.18 (t, J=3.6 Hz, 1H), 3.71 – 3.85 (m, 2H), 3.94 (s, 1H), 3.90 (s, 1H), 4.64 (d,
J=3.9 Hz, 1H), 4.83 (d, J=3.3 Hz, 1H), 5. 15 (s, 1H), 7.38 (d, J=8.1 Hz, 1H). Anal.
(C10H19NO5) calculated: C, 51.49; H, 8.21; N, 6.00. Found: C, 51.58; H, 8.15; N, 5.83.
8-Hydroxy-4,4-dimethyl-3,5,10-trioxa-tricyclo[6.2.1.02,6]undecan-9-one (14).
A mixture of quinic qcid (1) (20g, 104.1 mMol), p-totuenesulfonic acid monohydrate
(0.2g), 2,2-dimethoxypropane ( 38g, 364 mMol), and acetone ( 100 mL) was heated to
reflux for 2 hr. The reaction mixture was cooled down, and solvent was removed under
reduced pressure. The residue was dissolved in ethyl acetate (100 mL), washed with 5%
aqueous sodium bicarbonate (100 mL). The aqueous phase was back-extracted with ethyl
acetate (50x 2 mL). The combined organic extracts were dried (Na2SO4), filtered, and the
solvents were removed in vacuo. The residue was crystallized with hot ethyl acetate, got
white solid 14 16g (80% yield). mp: 147-149C Rf =0.3 (EtoAC: Hex=3:7). MS:
[M+Na]+=237. 1H NMR (CDCl3)  1.37 (s, 3H), 1.55 (s, 3H), 2.21 (dd, J= 14.7, 3.0 Hz,
1H), 2.30-2.44 (m, 2H), 2.68 (d, J=11.7 Hz, 1H), 2.83(s, 1H), 4.32-4.36 (m, 1H), 4.514.58 (m, 1H), 4.79 (dd, J=2.6, 6.3 Hz, 1H).
5,7-Dihydroxy-2,2-dimethyl-hexahydro-benzo[1,3]dioxole-5-carboxylic acid
propylamide (15). Lactone (14), (10g, 46.7 mMol), propylamine (30 mL), and glacial
acetic acid (10 mL) was refluxed under argon with oil bath (85C) for 45 min. Solvents
were removed under reduced pressure. The residue was washed with saturated sodium
bicarbonate solution (100 mL), extracted with ethyl acetate (100 x 3 mL). The combined
organic extracts were dried (Na2SO4), filtered, and the solvents were removed in vacuo.
The residue was crystallized with hot ethyl acetate, got white solid 15 9.7g (76% yield).
mp: 85-86C, Rf=0.15 (EtoAC: Hex=2:1). MS: [M+Na]+=296. 1H NMR (DMSO) 
0.83 (t, J=6.0 Hz, 3H), 1.24 (s, 3H), 1.38 (s, 3H), 1.40-1.45 (m, 2H), 1.61-1.64 (m, 2H),
1.72 (dd, J=14.7, 5.7 Hz, 1H), 2.04 (dd, J=14.7, 5.7 Hz, 1H), 3.01 (dd, J=6.6, 7.2 Hz,
2H), 3.80 (ddd, J=9.9, 6.3, 3.6 Hz, 2H), 4.31 (d, J=5.4 Hz, 1H), 5.01 (d, J=5.1 Hz, 1H), 5.
28 (s, 1H), 7.73 (t, J=5.7 Hz, 1H).
1,3,4,5-tetrahydroxy-cyclohexane-carboxylic acid propylamide (3a). The
amide (15) (5.0g) was dissolved in water (10mL), then added aq. 1M HCl (40 mL) at
room temperature. The reaction mixture was stirred at room temperature for 1hr. Solvent
was removed under reduced pressure. Residue HCl was removed by adding EtOEt (20 x
3 mL) under vacuo. The residue was further dried under oil pump. Collect product
3a.26g (100% yield). mp: 132-133C, Rf 0.03 (CHCl3 :MeOH:NH3OH =100:10:1); MS:
[M-H]-=232; 1H NMR (300 MHz, DMSO)  0.81 (t, J=6.0 Hz, 3H), 1.41 (ddd, J=13.8,
7.5, 6.9 Hz, 2H) 1.66-1.83 (m, 4H), 3.02 (dd, J=6.9, 6.6 Hz, 2H), 3.22 (t, J=6.0 Hz, 1H),
3.75 (ddd, J=13.8, 9.0, 5.7 Hz, 1H), 3.94 (s, 1H), 4.69 (d, J=4.5 Hz, 1H), 4.90 (d, J=5.4
Hz, 1H), 5.19 (d, J=3.6 Hz, 1H), 5. 47 (s, 1H), 7.76 (t, J=5.4 Hz, 1H). Anal. (C10H19NO5)
calculated: C, 51.49; H, 8.21; N, 6.00. Found: C, 51.57; H, 8.40; N, 6.01.
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2.4.2 Biology
All chemicals and solvents were purchased from Sigma Aldrich Chemical Co. (St.
Louis, MO) if not specified, and were used without any further purification. TNF-alpha
was purchased from Invitrogen (Carlsbad, CA). Great EscAPe SEAP Chemilumi Kit was
purchase from Clontech Lab, Inc. (Mountain View, CA).
2.4.2.1 A549SN cell line and culture
A549 cells (ATCC), which are a human lung adenocarcinoma cell line
representative of alveolar type II epithelium, were maintained in a 5% CO2 incubator at
37C using BME (Cellgrow) supplemented with 10% heat-inactivated fetal calf serum,
2mM L-glutamine (Gibco), 100U/mL penicillin-100 g/mL streptomycin (Gibco). The
plasmid NF-B-SEAP-ntp was cloned.117 For NF-κB transcription activity testing, A549
cells were transfected with NF-B-SEAP-ntp plasmid, this is the A549SN cell line.
2.4.2.2 NF-B activity – A549SN cell SEAP method
Day1: Plate NF-κB cells: (1) Plate NF-κB_SEAP A549 cells, 6.0x104 cells/well
in three 24 well plates, 1000 L DMEM complete medium: 10% heat inactivated FBS,
2mM L-Glu, 100U/mL or 100 g/mL Penn/Strep, 500 g/mL G418. (2) Incubate at 37C
incubator with 5% CO2. Day2: Treat cells with drugs: Cells are all alive, not confluent
(~25-40%). Treat cells with QA=1M, or other compounds @ 1 M (990 L 1% FBS
DMEM + 10 l (10/500) PBS diluted compounds from 5mM in DMSO), + 10 ng/mL
TNFα, for 24 hrs. Day 3: Measure SEAP activity: 24 h later, take out 50L medium.
Store at –20C. Use Clontech “Great EscAPe SEAP Chemiluminescence Detection Kit”
(Cat# K2041-1) to measure luminescence through microplate luninometer (Packard HT
microplate reader). Measure 1 second for once at RT. Cells left in plate were lysed in 250
l lysis buffer (10mMK2HPO4; 1mMKH2PO4; 1%Triton X100; 1mMDTT) for protein
quantification (Pierce BCA Protein Assay Kit, Microplate Procedure) and SEAP activity
was normalized to the total protein content. Inhibitory potency (IC50) was determined
from dose-response curves (n=3, separate experiment).
2.4.2.3 MTS -cytotoxicity studies in cultured human lung adenocarcinoma A549SN cells
A549SN cells were suspended in culture medium at a density of 10 × 104
cells/mL. Then 1× 104 cells in 200 μL were plated into 96-well flat-bottom plates.
Following incubation for 24 hours at 37°C, drugs, vehicles and controls consisting only
of medium and cells were dispensed in 200 µL volumes in duplicate into the appropriate
wells, and incubated for 18 hours. QA derivatives were tested at concentrations ranging
from 0.01 to 100 uM. Cell viability was assessed by the MTS-CellTiter 96® aqueous
non-radioactive cell proliferation assay (Promega, Madison, WI, USA) according to the
manufacturer’s protocol after 2 hours of culture. The number of living cells in the culture
28

is directly proportional to the absorbance at 490 nm by a formazan product bioreduced
from MTS by living cells. Absorbance was measured using a DTX 880 multimode
detector (Beckman Coulter, Fullerton, CA). The absorbance of media-only well was
subtracted from reading of control or treated wells.
2.4.2.4 Anti-oxidant activity test method
The DPPH and all standard antioxidant compounds including trolox were
dissolved in 50% acetone. The DPPH stock solution at a concentration of 0.625 mM was
prepared monthly and kept at 4°C in dark. The 0.208 mM fresh DPPH working solution
was made daily by further diluting the stock solution in 50% acetone for each test. Stock
solutions of CA, CGA, AA and compound 3 were prepared in 50% acetone at
concentrations of 10 mM, respectively, and stored at 4°C. A series of working solutions
were made by appropriate dilutions of the above standard phenolic acid stock solutions
with 50% acetone.
2.4.2.5 Conventional colorimetric analysis
The conventional colorimetric DPPH scavenging capacity assay was performed
according to a previously described laboratory protocol.116 Briefly, an aliquot of 500 L
of different concentrations of sample extracts in 50% acetone was added to 500 L of
0.208 mM DPPH solution. The initial concentration was 0.104 mM for DPPH in all
reaction mixtures. Each mixture was vortexed for a few seconds and test immediately.
The absorbance (A) of each reaction mixture at 515 nm was measured against a blank of
50% acetone using a UV-visible spectrometer. The level of DPPH remaining for each
reaction time was calculated as: % DPPH remaining=(A sample-t / A control) x 100.
2.4.2.6 Carrageenan induced paw edema
Carrageenan 1% in sterile filtered saline (10 mg/mL) using lysing matrix D tubes,
add saline to the tube first, then add Carrageenan, vortex for 2-3 minutes, heat in 60°C
water bath for 1 hour, vortex 2-3 min, inject 100 L into plantar region of right hind paw.
Dexamethasone: 0.5 mg/kg in normal saline with 2% EtOH administered intraperitoneally (i.p.) Recommended volume 10 mL/kg (2-3 mL depending on weight).
Should be ~ 200-300 g per rat, will prepare 100 g/mL solution and calculate the
injection volume based on the weight of the rat. Treatment: 50 mg/kg in 90% normal
saline, 5% EtOH, 5% stepantex administered i.p. Rat were tattooed to draw line on L and
R hind paw below ankle and above plantar region. Take R and L paw measurement
before treatment. Inject drug solution or vehicle into the lower right quadrant by i.p.
Inject 100 L 1%Carrageenan saline solution into plantar region of R hind paw. Inject
100 L Normal Saline into plantar region of L hind paw. Measure volume of both paws
at 1, 3, 5 hours.
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CHAPTER 3. DESIGN AND SYNTHESIS OF QUINIC ACID DERIVATIVE
ESTERS AND COMPOUND WITH DOUBLE BOND
3.1 Introduction
Hot water Cat’s claw extracts (e.g., C-Med 100) have very low alkaloid content
(<0.5%) and yet retain significant immune enhancing activity. Recently, quinic acid (QA)
esters have been identified as biologically active components in the extract.1 Base
hydrolysis of the extract dramatically reduces biological activity. For example, the
lactone ester of QA (QAL) inhibits proliferation of mitogen-stimulated mouse
lymphocytes, whereas QA does not affect proliferation.2 Further, base hydrolysis of the
extract dramatically reduces its anti-proliferative effect against HL-60 and human
mononuclear cells.1 Together, these data suggest the ester derivatives of QA found in the
extract comprise a significant fraction of the biological activity.
The first three steps of QA catabolism are an NAD-dependent oxidation to form
dehydroquinate, followed by two successive dehydrations to form dehydroshikimate and
shikimate.16 Several research groups have made QA derivatives to target the QA
catabolism enzymes. Kim made analogues as influenza neuraminidase inhibitors with
potent snti-anfluenza activity.91 Sanchez-Sixto and Metaferia made compounds to kill
Mycobacterium tuberculosis.92,93 Payne designed derivatives to act as type II
dehydroquinase inhibitors.94 We have identified water soluble QA amide 3 which possess
potent anti-inflammatory activity.118,119 QA amide lead 3 will serve as a new template for
anti-inflammatory agents. We plan to investigate the importance of the hydroxyl groups
on the cyclohexane ring by preparing the dehydroquinate amide 3 analogs. We also plan
to investigate the importance of double bonds on the cyclohexane ring by preparing the
dehydroquinate double bond amide 3 analogs. We hypothesize these modifications will
retain anti-inflammatory activity with enhanced resistance to microbial degradation.
Because the first three steps of QA catabolism by bacteria are to form dehydroquinate,
followed by two successive dehydrations to form dehydroshikimate and shikimate.16 We
assume QA degradation by the bacteria will not take place when the new substrates lack
of hydroxyl groups and/or having a double bond.
Chlorogenic acid (3-caffeoyl-D-quinic acid; CGA) is an ester formed between
caffeic acid (CA) and QA. CGA and other polyphenolic compounds found in fruits act as
potent antioxidants. For example, CGA and CA are both capable of scavenging NO•,64 a
pro-inflammatory oxygen radical produced via the L-arginine pathway by infiltrating
leucocytes.65 Interestingly, QA does not possess antioxidant activity suggesting
alternative mechanisms underlie its anti-inflammatory activity.64 In 2001, Sefkow has
synthesized CGA, 1-, 4-, and 5-Caffeoylquinic Acid as antioxidant.95,96 Those esters
have many other properties such as antibacterial, antimutagenic, antitumor, and
antiviral.97 Metaferia synthesized QA derivatives macrolides that inhibit breast cancer
cell migration in vitro.98 QA amide 3 does not possess antioxidant activity as showed in
Chapter 2. Based on QA amide 3 lead which serves as a new template for antiinflammatory agents, we are now planning to investigate to see if antioxidant groups are
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added for having both anti-inflammatory and antioxidant activity. We will prepare a
serial of QA amide ester analogs with antioxidant groups such as caffeic acid, sinapic
acid. We hypothesize these modifications will retain anti-inflammatory activity with
additional antioxidant property. Furthermore, they will be hydrolyzed by the microflora,
for an example, CGA is hydrolyzed into Caffeic acid and QA.77,78 Both caffeic acid and
QA amide will not be consumed by gut bacteria, and easily be absorbed in animal
digestive tract.
3.2 Results and Discussion
3.2.1 Synthesis of Quinic Acid Derivatives
Synthesis of 3, 4-Dihydroxy-cyclohexanecarboxylic acid propylamide 18 and
1,3,4-Trihydroxy-cyclohexanecarboxylic acid propylamide 20 were carried out as shown
in Scheme 3-1.67, 68, 114, 120 The synthesis of the lactone 2 was carried out using quinic
acid 1 and PTSA in refluxing benzene and DMF according to the procedure of Neelu
Kaila et al. with minor revision. The lactone 2 was then allowed to refluxed with
ClC(S)Cl and imidazole in ClCH2CH2Cl, and then resulting imidazole-1-carbothioic acid
O-(9-oxo-4-thioxo-3,5,10-trioxa tricyclo[6.2.1.02,6] undec-8-yl) ester 16. Compound 16
was treated with Bu3SnH/xylene, then Bu3SnH and AIBN/xylene to give compounds 4Hydroxy-6-oxa-bicyclo[3.2.1]octan-7-one 17 and 1,4-Dihydroxy-6-oxabicyclo[3.2.1]octan-7-one 19. The lactones 17 and 19 were then allowed to react with Npropyl amine with acetic acid at 85C, and then resulting amides 18, and 20 respectively.
Amides 18, and 20 were purified using flash chromatography.114
Synthesis of 3-(4-Hydroxy-3, 5-dimethoxy-phenyl)-acrylic acid 2,3,5-trihydroxy5-propylcarbamoyl-cyclohexyl ester 25 was carried out as shown in Scheme 3-2.96,115,121
The synthesis of the lactone 14 was carried out using quinic acid 1 and PTSA in refluxing
2,2-DMP and acetone. The lactone 14 was then allowed to to react with N-propyl amine
with acetic acid at 85C, and then resulting amide 15. The synthesis of compound 22
was carried out using sinapic acid 21 treated with Ac2O in pyridine, DMAP, at room
temperature; Compounds 15 and 22 were mixed in CH2Cl2, treated with DMAP, DIC, at
room temperature, and then resulting 3-(4-Acetoxy-3,5-dimethoxy-phenyl)-acrylic acid
6-hydroxy-2,2-dimethyl-6-propylcarbamoyl-hexahydro-benzo[1,3]dioxol-4-yl ester 23.
Ester 23 was treated with 1N HCl for 20 min, obtained compound 24; ester 23 was
treated with 1N HCl for 7 days, obtained compound 25. Compounds 23, 24, and 25 were
purified using flash chromatography.
3-(4-Hydroxy-3, 5-dimethoxy-phenyl)-acrylic acid 3,4,5-trihydroxy-1propylcarbamoyl-cyclohexyl ester 29 was synthesized as shown in Scheme 3-3.96,115,121
The synthesis of the lactone 14 was carried out using quinic acid 1 and PTSA in refluxing
2,2-DMP and acetone.The synthesis of compound 26 was carried out in two steps, first
using sinapic acid 21 treated with Ac2O in pyridine, DMAP, at room temperature; then
the product was refluxed in SOCl2 and CH2Cl2. Compounds 14 and 26 were mixed in
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CH2Cl2, treated with DMAP, Pyridine, at room temperature, and then resulting ester 27.
Ester 27 was allowed to react with N-propyl amine with acetic acid at 85C, and then
resulting ester 28; Compound 29 was carried out using ester 28 treated with 1N HCl for 5
days. Compounds 29 were purified using flash chromatography.
3-(4-Hydroxy-3,5-dimethoxy-phenyl)-acrylic acid 2,3,5-trihydroxy-5propylcarbamoyl-cyclohexyl ester 33 was synthesized as shown in Scheme 3-4.96,115,121
The synthesis of the lactone 14 was carried out using quinic acid 1 and PTSA in refluxing
2,2-DMP and acetone. lactone 14 was allowed to react with N-propyl amine with acetic
acid at 85C, and then resulting ester 15; The synthesis of compound 31 was carried out
in two steps, first using caffeic acid 30 treated with Ac2O in pyridine, DMAP, at room
temperature; then the product was refluxed in SOCl2 and CH2Cl2. Compounds 15 and 31
were mixed in CH2Cl2, treated with DMAP, Pyridine, at room temperature, and then
resulting ester 32. Compound 33 was carried out using ester 32 treated with 1N HCl for 5
days. Compounds 33 were purified using flash chromatography.
The synthesis of 1,4,5-Trihydroxy-cyclohex-2-enecarboxylic acid propylamide 38
was shown in Scheme 3-5.122-124 Compound 34 was synthesized by using quinic acid 1
and PTSA in refluxing benzaldehyde and benzene. lactone 34 was allowed to react with
NBS, AIBN, reluxed in benzene, and then resulting ester 35; The synthesis of compound
36 was carried out using compound 35 treated with DBU, tert-butyldimethylsilyl chloride
in acetonitrile, refluxed. Compounds 36 was allowed to react with N-propyl amine with
acetic acid at 85C, and then resulting amide 37. Compound 38 was carried out using
amide 37 treated with 1M TBAF solution. Compounds 38 were purified using flash
chromatography.
3.2.2 Biology Testing of Dehydroxyl QA Amides and Esters
The results of dehydroxyl QA amides anti-inflammatory high throughput
screening are presented in Figure 3-1. Both compounds 18 and 20 showed NF-B
inhibition at concentration 1 M. The extent of NF-B inhibition was close to positive
control drug dexamethasone. The compounds 18, 20 and 38 were designed to retain antiinflammatory activity while having enhanced resistance to microbial degradation. Their
biological activities were tested by other researchers. The compounds 25, 29 and 33 were
designed to retain anti-inflammatory activity with additional antioxidant properties.
Furthermore, they were hydrolyzed by the microflora, for an example, 25 was hydrolyzed
into SA and 3. Both SA and 3 will not be consumed by gut bacteria, and easily be
absorbed in animal digestive tract. This was done by other researchers, and not reported
here. Mechanistic studies and pre-clinical efficacy studies of these newly designed
compounds in various in vitro and in vivo models are on-going by other researchers, and
are not reported in this dissertation.
Next, we determined the anti-oxidant potential of QA derivatives using the 2, 2diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging method.116 As expected,
caffeic acid (CA), sinapic acid (SA) and compound 25 showed strong anti-oxidant
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Figure 3-1. NF-B inhibition by KZ-41 derivatives using A549 cells stably transfected
with a secreted alkaline phosphatase (SEAP) reporter. NF-B activity was measured 18
hours after addition of TNF- (10 ng/mL) and QA synthesized derivatives (18, 20; 1 M).
Dexamethasone (Dex; 1 M) was used as a positive control. Data are presented as
percent (%) inhibition relative to control (ctl; TNF- alone) and represent mean %
inhibition ±standard deviation (n=3). Blank: media only.
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activity, while 24 had no anti-oxidant activity (Figure 3-2). The fact that 24 does not
possess anti-oxidant activity is consistent with a previous report.64 Because it does not
bear a free phenolic group could act as antioxidants.80, 81
3.3 Conclusions
The dehydroxyl QA amides 18 and 20 were synthesized. They showed NF-B
inhibition at concentration 1 M. The extent of NF-B inhibition was close to positive
control drug dexamethasone. The dehydroxyl QA amide with a double bond 38 was also
synthesized. The QA amide esters 24, 25, 29 and 33 were designed and synthesized. As
expected, compound 25 showed strong anti-oxidant activity. Furthermore, they were
hydrolyzed by the microflora, for an example, 25 was hydrolyzed into SA and 3. Both
SA and 3 will not be consumed by gut bacteria, and easily be absorbed in animal
digestive tract. Mechanistic studies and pre-clinical efficacy studies of these newly
designed compounds in various in vitro and in vivo models are on-going by other
researchers, and are not reported in this dissertation.
3.4 Experimental
3.4.1 Chemistry
All reagents and solvents were purchased from Sigma Aldrich Chemical Co. (St.
Louis, MO), Fischer Scientific (Pittsburgh, PA), and TCI (Portland, OR), and were used
without any further purification. Thin layer chromatography (TLC) was performed on
silica gel chromatogram plates purchased from Analtech, Inc. Flash chromatography was
performed either on silica gel (60 Å, 200 -425 mesh) or on pre-packed silica gel columns
by using a Horizon HPFC system (Biotage, Charlottesville, VA). Molecular masses were
collected with electron spray ionization mass spectra (ESI-MS) on a Bruker/Hewlett
Packard Esquire LC/MS instrument. Nuclear magnetic resonance (NMR) spectra for 1H
NMR and 13C NMR were recorded on a Bruker ARX 300 instrument and/or a Varian
Inova-500 MHz instrument. The chemical shifts value (δ) are reported in parts per
million (ppm) relative to tetramethylsilane (TMS), and coupling constants (J) were
reported in hertz. Peaks are abbreviated as were indicated as follows: s, singlet; d, doublet;
t, triplet; m, multiplet. Deuterated solvents were purchased from Cambridge Isotope
Laboratories, Inc. Melting points were determined on a Fisher-Johns melting point
apparatus and are uncorrected. Elemental analyses (C, H, N) were performed by Atlantic
Microlab Inc. (Norcross, GA), and are accepted within ±0.4 of the theoretical values.
High performance liquid chromatography (HPLC) separation was performed on a
Hewlett Packard LC instrument with model 1100 system.
Imidazole-1-carbothioic acid O-(9-oxo-4-thioxo-3, 5, 10-trioxa tricycle
[6.2.1.02, 6] undec-8-yl) ester (16). In a 250 mL round-bottom flask fitted with a
stirring bar, reflux condenser, and argon inlet, 7.0 mL of thiophosgene (90 mmol) was
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Figure 3-2. Determining antioxidant activity by reaction kinetics of DPPH. Caffeic acid
(CA), sinapic acid (SA), compound 24 and 25 were prepared in 50% acetone. The
conventional colorimetric DPPH scavenging capacity was determined by UV absorption
measured at 515 nm. CA, SA and compound 25 showed strong anti-oxidant activity,
while 24 had no anti-oxidant activity.
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added dropwise under argon to rapidly stirred suspension of imidazole (25g) in dry
ClCH2CH2Cl (150 mL). Following completion of the addition, the mixture was agitated
30 min. Then added lactone (1, 5g, 30 mMol) in one portion, refluxed 3 hr, cooled to rt.
The solvent was removed immediately under high vacuum to get dry brown oil. Added
cold water (100 mL x 2), washed the residue carefully, then carefully washed the residue
with acetone (5 mL x 3), filtered, collect white solid 16, 4.61 g (47% yield). MS:
[M+Na]+: 349; 1H NMR (300 MHz, DMSO)  2.40 (d, J=12 Hz, 1H), 2.79 -2.84 (m,
1H), 3.03 (dd, J=15.0, 3.0 Hz, 1H), 3.80 – 3.94 (m, 1H), 5.33-5.40 (m, 2H), 5.63 – 5.70
(m, 1H), 7.12 (d, J=1.0 Hz, 1H), 7.84 (d, J=1 Hz, 1H), 8.54 (s, 1H).
4-Hydroxy-6-oxa-bicyclo[3.2.1]octan-7-one (17). In a 200 mL round-bottom
flask fitted with a stirring bar, reflux condenser, 3.26 g Ester 16 (10 mmol), was
suspended in 80 mL dry xylene, refluxed under argon. Treated with 2.51 mL TBTH first,
after 30 min, added 2.51 mL TBTH more, after another 1 hr, added 4.0 mL TBTH and
0.02 g AIBN, refluxed for 2.5 hr. The solvent was removed under high vacuum. Reaction
residue was purified by flash column (Hex : EtOAc =1:1). Collect product 17, 110 mg
(8% yield). Rf 0.13 (Hex : EtOAc =1:1); MS: [M+Na]+: 165; 1H NMR (300 MHz,
DMSO) 1.66-1.83 (m, 5H), 2.10 -2.20 (m, 1H), 2.24 (d, J=7.8 Hz, 1H), 2.24 (s, 1H), 3.89
(m, J=4.5 Hz, 1H), 4.54 (t, J=5.4 Hz, 1H), 5.21 (d, J=3.3 Hz, 1H).
3,4-Dihydroxy-cyclohexanecarboxylic acid propylamide (18). In a 50 mL
round-bottom flask fitted with a stirring bar, reflux condenser, 0.25g Lactone 17 (1.24
mmol), and propylamine (0.83 mL, 0.6g, 10.13 mmol) were combined, then glacial acetic
acid (1.1 mL, 0.75 g, 12.71 mmol) was added. The solution was warmed to 85C in oil
bath for 30 min, at which time TLC (CHCl3 :MeOH:NH3OH =100:10:1) indicated
complete consumption of the starting lactone. The solvent was removed under reduced
pressure. The residue was purified by flash column with same solvent as TLC. Collect
product 17, 256mg (64% yield). mp: 105-107C, Rf 0.15 (CHCl3 :MeOH:NH3OH
=100:10:1); MS: [M+Na]+ =224; 1H NMR (300 MHz, DMSO)  0.81 (t, J=6.0 Hz, 3H),
1.41-1.61 (m, 5H), 1.76 (d, J=3.0 Hz, 1H), 1.81 (d, J=3.0 Hz, 2H), 2.12 (t, J=1 Hz, 1H),
2.96 (dd, J=6.3, 12.6 Hz, 2H), 3.08 (dd, J=4.5, 9.0 Hz, 2H), 4.55 (d, J=3.0 Hz, 1H), 4.60
(d, J=3.0 Hz, 1H), 7.67 (t, J=5.4 Hz, 1H). Anal. (C10H19NO3) calculated: C, 59.68; H,
9.52; N, 6.96. Found: C, 59.25; H, 9.46; N, 6.91.
1,4-Dihydroxy-6-oxa-bicyclo[3.2.1]octan-7-one (19). In a 200 mL round-bottom
flask fitted with a stirring bar, reflux condenser, 3.26 g Ester 16 (10 mmol), was
suspended in 80 mL dry xylene, refluxed under argon. Treated with 2.51 mL TBTH first,
after 30 min, added 2.51 mL TBTH more, after another 1 hr, added 4.0 mL TBTH and
0.02 g AIBN, refluxed for 2.5 hr. The solvent was removed under high vacuum. Reaction
residue was purified by flash column (Hex : EtOAc =1:1). Collect product 19, 220 mg
(14% yield). Rf 0.08 (Hex : EtOAc =1:1); MS: [M+Na]+: 181; 1H NMR (300 MHz,
DMSO) 1.66-1.83 (m, 4H), 2.10 -2.20 (m, 1H), 2.24 (d, J=7.8 Hz, 1H), 2.24 (s, 1H), 3.89
(m, J=4.5 Hz, 1H), 4.54 (t, J=5.4 Hz, 1H), 5.21 (d, J=3.3 Hz, 1H), 5.84 (s, 1H).
1,3,4-Trihydroxy-cyclohexanecarboxylic acid propylamide (20). In a 50 mL
round-bottom flask fitted with a stirring bar, reflux condenser, 0.30g Lactone 19 (1.90
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mmol), and propylamine (0.83 mL, 0.6g, 10.13 mmol) were combined, then glacial acetic
acid (1.3 mL, 0.94 g, 15.93 mmol) was added. The solution was warmed to 85C in oil
bath for 30 min, at which time TLC (CHCl3 :MeOH:NH3OH =100:10:1) indicated
complete consumption of the starting lactone. The solvent was removed under reduced
pressure. The residue was purified by flash column with same solvent as TLC. Collect
product 20, 240 mg (58% yield). mp: 151-154C, Rf 0.12 (CHCl3 :MeOH:NH3OH
=100:10:1); MS: [M+Na]+ =240; 1H NMR (300 MHz, DMSO)  0.81 (t, J=4.5 Hz, 3H),
1.37-1.44 (m, 3H), 1.51-1.71 (m, 5H), 3.00 (q, J=6.6 Hz, 2H), 3.12 (m, 1H), 3.45 (m, 1H),
4.49 (d, J=1.8 Hz, 1H), 4.52 (d, J=3.0 Hz, 1H), 5.17 (s, 1 H), 7.67 (t, J=5.4 Hz, 1H). Anal.
(C10H19NO4) calculated: C, 55.28; H, 8.81; N, 6.45. Found: C, 55.12; H, 8.72; N, 6.50.
3-(4-Acetoxy-3,5-dimethoxy-phenyl)-acrylic acid (22). In a 50 mL roundbottom flask fitted with a stirring bar, 1.0 g Sinapic acid 21 (4.46 mmol), and 0.02g
DMAP were combined in 15 mL anhydrous pyridine, then Ac2O (0.56 mL, 0.57 g, 5.57
mmol) was added under ice bath. The reaction mixture was stirred for 2 hr, then poured
onto crushed ice. The aqueous phase was acidified with 2 M aqueous HCl (pH =2) and
extracted with EtOAc (3 x 80mL). The combined organic extracts were dried over
Na2SO4, filtered, the solvent was removed under reduced pressure. Titration of the
residue with hexane containing small amount of EtOAc afforded acetyl sinapic acid 22
1.2 g (98% yield), white powder. MS: [M-H]- =265.
3-(4-Acetoxy-3,5-dimethoxy-phenyl)-acrylic acid 6-hydroxy-2,2-dimethyl-6propylcarbamoyl-hexahydro-benzo[1,3]dioxol-4-yl ester (23). In a 100 mL roundbottom flask fitted with a stirring bar, lactone (1, 0.7g, 2.56 mMol), acetyl sinapic acid
22, (0.72 g, 2.70 mmol) were combined in 50 mL anhydrous CH2Cl2 under argon, 0.05 g
DMAP was added, then 0.6 mL DIC was added at rt, stirred for 2 days. Solid urine was
filtered out. Reaction mixture was washed with 0.5 N HCl, extracted with CH2Cl2 (3 x
80mL). The combined organic extracts were dried over Na2SO4, filtered, the solvent was
removed under reduced pressure. Residue was purified by flash column with solvent
mixture of Hexane : Acetone (10/3, v/v). Collect white solid product 23, 825 mg (62%
yield). Rf 0.15 (Hexane:Acetone =10:3); MS: [M+Na]+=544. 1H NMR (300 MHz,
DMSO) 0.81 (t, J=4.5 Hz, 3H), 0.85 (t, J=2.1 Hz, 1H), 1.27 (s, 3H), 1.40 -1.41 (m, 2H),
1.43 (s, 3H), 1.79 (d, J=4.8 Hz, 2H), 1.98 (d, J=9.0 Hz, 1H), 2.25(t, J=4.8 Hz, 3H), 3.02
(m, 2H), 3.80 (s, 6H), 4.14 (t, J=3.9 Hz, 1H), 4.44 (d, J=3.0 Hz, 1H), 5.38 (q, J=4.9 Hz,
1H), 5. 49 (s, 1H), 6.75 (d, J=9.9 Hz, 1H), 7.16 (s, 2H), 7.70 (d, J=9.9 Hz, 1H), 7.76 (t,
J=3.6 Hz, 1H).
3-(4-Acetoxy-3,5-dimethoxy-phenyl)-acrylic acid 2,3,5-trihydroxy-5
propylcarbamoyl-cyclohexyl ester (24). In a 50 mL round-bottom flask fitted with a
stirring bar, ester 23, (0.23 g, 0.44 mmol) were dissoved in 5 mL THF, then 15 mL
aqueous 1 N HCl was added at rt, stirred for 20 min. Reaction mixture was saturated with
Na HCO3 solution, extracted with EtOAc (3 x 80mL). The combined organic extracts
were dried over Na2SO4, filtered, the solvent was removed under reduced pressure.
Collect white solid product 24, 200 mg (95% yield). MS: [M+Na]+=504. 1H NMR (300
MHz, DMSO) 0.81 (t, J=4.5 Hz, 3H), 1.25 (m, 2H), 1.41 (m, 2H), 1.78 (d, J=15 Hz, 1H),
1.93 (m, 2H), 2.25(s, 3H), 3.02 (m, 2H), 3.58 (m, 1H), 3.81 (s, 6H), 4.10 (t, J=3.9 Hz,
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1H), 5.05 (d, J=6.0 Hz, 1H), 5.28 (q, J=6.3 Hz, 1H), 5. 59 (s, 1H), 5.70 (d, J=3.9 Hz, 1H),
6.75 (d, J=16 Hz, 1H), 7.16 (s, 2H), 7.63 (d, J=16 Hz, 1H), 7.76 (t, J=3.6 Hz, 1H).
3-(4-Hydroxy-3,5-dimethoxy-phenyl)-acrylic acid 2,3,5-trihydroxy-5propylcarbamoyl-cyclohexyl ester (25). In a 100 mL round-bottom flask fitted with a
stirring bar, ester 23, (0.50 g, 0.96 mmol) were dissoved in 10 mL THF, then 30 mL
aqueous 1 N HCl was added at rt. The reaction mixture was stirred at rt, and progress was
monitored by ESI-MS. After 7 days, reaction was completed. Reaction mixture was
killed with Na HCO3 solution, and saturated with NaCl, extracted with EtOAc (3 x
80mL). The combined organic extracts were dried over Na2SO4, filtered, the solvent was
removed under reduced pressure. The residue was purified by flash column
(CHCl3 :MeOH:NH3OH =100:10:1), Collect white solid product 25, 210 mg (50% yield).
Rf=0.16 (CHCl3 :MeOH:NH3OH =100:10:1), MS: [M+Na]+=462. 1H NMR (300 MHz,
DMSO) 0.80 (t, J=4.5 Hz, 3H), 1.41 (m, 2H), 1.75 (d, J=9.0 Hz, 1H), 1.89 (m, 1H),1.98
(m, 2H), 3.02 (m, 2H), 3.56 (m, 1H), 3.81 (s, 6H), 4.10 (s, 1H), 5.01 (d, J=3.3 Hz, 1H),
5.28 (q, J=3.0 Hz, 1H), 5. 58 (s, 1H), 5.67 (d, J=3.0 Hz, 1H), 6.52 (d, J=9.6 Hz, 1H), 7.02
(s, 2H), 7.56 (d, J=9.6 Hz, 1H), 7.75 (t, J=3.6 Hz, 1H), 8.92 (s, 1H). Anal. (C21H29NO9.
0.33 H2O) calculated: C, 56.62; H, 6.71; N, 3.14. Found: C, 56.53; H, 6.75; N, 3.00.
Acetic acid 4-(2-chlorocarbonyl-vinyl)-2,6-dimethoxy-phenyl ester (26). In a
50 mL round-bottom flask fitted with a stirring bar, 1.0 g Sinapic acid 21 (4.46 mmol),
and 0.02g DMAP were combined in 15 mL anhydrous pyridine, then Ac2O (0.56 mL,
0.57 g, 5.57 mmol) was added under ice bath. The reaction mixture was stirred for 2 hr,
then poured onto crushed ice. The aqueous phase was acidified with 2 M aqueous HCl
(pH =2) and extracted with EtOAc (3 x 80mL). The combined organic extracts were
dried over Na2SO4, filtered, the solvent was removed under reduced pressure. Titration of
the residue with hexane containing small amount of EtOAc afforded acetyl sinapic acid
22 1.2 g (98% yield), white powder. MS: [M-H]- =265.
In a 50 mL round-bottom flask fitted with a stirring bar, 0.6g acetyl sinapic acid
22 (2.26 mmol), was dissolved in 20 mL CH2Cl2, then 0.8 mL SOCl2 was added. The
reaction mixture was refluxed 3 hr under argon. The solvent was removed under reduced
pressure, residue was white solid 26.
3-(4-Acetoxy-3,5-dimethoxy-phenyl)-acrylic acid 4,4-dimethyl-9-oxo-3,5,10trioxa-tricyclo[6.2.1]undec-8-yl ester (27). In a 100 mL round-bottom flask fitted with a
stirring bar, lactone (14, 0.6g, 2.56 mMol), compound (26, 2.26 mmol) were combined
in 50 mL anhydrous CH2Cl2 under argon, 0.5 g DMAP was added, then 10 mL anhydrous
pyridine was added at rt, stirred overnight under argon. The solvent was removed under
reduced pressure. Reaction mixture was washed with 50 mL 0.5 N HCl, extracted with
EtOAc (3 x 50mL). The combined organic extracts were dried over Na2SO4, filtered, the
solvent was removed under reduced pressure. Residue was purified by flash column with
solvent mixture of Hexane : EtOAc (7/3, v/v). Collect white solid product 27, 605 mg
(58% yield). Rf 0.14 (Hexane:EtOAc =7:3); MS: [M+Na]+=485. 1H NMR (300 MHz,
DMSO) 1.27 (s, 3H), 1.47 (s, 3H), 2.26(t, J=4.8 Hz, 3H), 2.31 (d, J=3.3 Hz, 1H), 2.43 2.46 (m, 2H), 3.02 (m, 1H), 3.81 (s, 6H), 4.58 (d, J=4.9 Hz, 1H), 4.60 (td, J=8.8, 3.0 Hz,
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1H), 4.96 (dd, J=6.0, 2.4 Hz, 1H), 6.81 (d, J=16 Hz, 1H), 7.19 (s, 2H), 7.70 (d, J=16 Hz,
1H).
1,3,4,5-tetrahydroxy-cyclohexane-carboxylic acid propylamide (28). In a 50
mL round-bottom flask fitted with a stirring bar, reflux condenser, 0.40 g Lactone 27
(0.87 mmol), and propylamine (0.83 mL, 0.6g, 10.13 mmol) were combined, then glacial
acetic acid (0.64 mL, 0.46 g, 7.80 mmol) was added. The solution was warmed to 85C
in oil bath for 45 min, at which time TLC (CHCl3 :MeOH:NH3OH =100:10:1) indicated
complete consumption of the starting lactone. The solvent was removed under reduced
pressure. Residue was washed with Na HCO3 solution, and saturated with NaCl,
extracted with EtOAc (3 x 80mL). The combined organic extracts were dried over
Na2SO4, filtered, the solvent was removed under reduced pressure. Collect product white
solid 28, one spot, Rf 0.5 (CHCl3 :MeOH:NH3OH =100:10:1); MS: [M+NH4]+ =539;
used for next reaction without further purification.
3-(4-Hydroxy-3,5-dimethoxy-phenyl)-acrylic acid 2,3,5-trihydroxy-5propylcarbamoyl-cyclohexyl ester (29). In a 100 mL round-bottom flask fitted with a
stirring bar, ester 28, (0.70 mmol) were dissoved in 5 mL THF, then 15 mL aqueous 1 N
HCl was added at rt. The reaction mixture was stirred at rt, and progress was monitored
by ESI-MS. After 5 days, reaction was completed. Reaction mixture was killed with
NaHCO3 solution, and saturated with NaCl, extracted with EtOAc (3 x 80mL). The
combined organic extracts were dried over Na2SO4, filtered, the solvent was removed
under reduced pressure. The residue was purified by flash column with solvent
(CHCl3 :MeOH:NH3OH =100:10:1), Collect white solid product 29, 105 mg (34% yield).
Rf=0.06 (CHCl3 :MeOH:NH3OH =100:10:1), MS: [M+Na]+=462. 1H NMR (300 MHz,
DMSO) 0.80 (t, J=7.2 Hz, 3H), 1.32 - 1.44 (m, 2H), 1.95 -2.05 (m, 4H),2.40(m, 1H),
3.02 (m, 2H), 3.57 (m, 2H), 3.81 (s, 6H), 4.35(d, J=4.5 Hz, 1H), 4.65 (d, J=4.5 Hz,1H),
5.34 (d, J=5.4 Hz, 1H), 6.45 (d, J=16 Hz, 1H), 7.00 (s, 2H), 7.50 (d, J=16 Hz, 1H), 8.03 (t,
J=5.7 Hz, 1H), 8.94 (s, 1H). Anal. (C21H29NO9. 1.33H2O) calculated: C, 54.42; H, 6.89;
N, 3.02. Found: C, 54.56; H, 6.79; N, 2.98.
Acetic acid 2-acetoxy-4-(2-chlorocarbonyl-vinyl)-phenyl ester (31). In a 50 mL
round-bottom flask fitted with a stirring bar, 1.0 g caffeic acid 30 (5.61 mmol), and
0.02g DMAP were combined in 15 mL anhydrous pyridine, then Ac2O (1.4 mL, 1.42 g,
14.01 mmol) was added under ice bath. The reaction mixture was stirred for 2 hr, then
poured onto crushed ice. The aqueous phase was acidified with 2 M aqueous HCl (pH =2)
and extracted with EtOAc (3 x 80mL). The combined organic extracts were dried over
Na2SO4, filtered, the solvent was removed under reduced pressure. Titration of the
residue with hexane containing small amount of EtOAc afforded acetyl caffeic acid 1.2 g
(98% yield), white powder. MS: [M-H]- =263.
In a 50 mL round-bottom flask fitted with a stirring bar, 0.7g acetyl caffeic acid
(2.65 mmol), was dissolved in 20 mL CH2Cl2, then 0.8 mL SOCl2 was added. The
reaction mixture was refluxed 3 hr under argon. The solvent was removed under reduced
pressure, residue was white solid 31.

44

3-(3,4-Diacetoxy-phenyl)-acrylic acid 6-hydroxy-2,2-dimethyl-6propylcarbamoyl-hexahydro-benzo[1,3]dioxol-4-yl ester (32). In a 100 mL roundbottom flask fitted with a stirring bar, compound 15 (0.7g, 2.56 mMol), compound (31,
2.26 mmol) were combined in 50 mL anhydrous CH2Cl2 under argon, 0.05 g DMAP was
added, then 10 mL anhydrous pyridine was added at rt, stirred overnight under argon.
The solvent was removed under reduced pressure. Reaction mixture was washed with 50
mL 0.5 N HCl, extracted with EtOAc (3 x 50mL). The combined organic extracts were
dried over Na2SO4, filtered, the solvent was removed under reduced pressure. Residue
was purified by flash column with solvent mixture of CH2Cl2:MeOH(98/2, v/v). Collect
white solid product 32, 750 mg (56% yield). Rf 0.44 (CH2Cl2:MeOH =98:2); MS:
[M+Na]+=442. 1H NMR (300 MHz, DMSO) 0.81 (t, J=7.5 Hz, 3H),1.26 (s, 3H), 1.33 1.40 (m, 2H), 1.41(s, 3H),1.78 (d, J=9.0 Hz, 2H),1.99 (d, J=5.0 Hz, 1H), 2.24 – 2.30 (m,
2H), 2.31 (s, 6H), 2.98 – 3.06 (m, 2H), 4.13 (m, 1H), 4.42 (m, 1H), 5.31 – 5.41 (m, 1H),
5.46 ( s, 1H), 6.64 (d, J=16 Hz, 1H), 7.32 (d, J=8.4, 1H), 7.65 (d, J=16 Hz, 1H), 7.64 7.68 (m, 2H).
3-(4-Hydroxy-3,5-dimethoxy-phenyl)-acrylic acid 2,3,5-trihydroxy-5propylcarbamoyl-cyclohexyl ester (33). In a 100 mL round-bottom flask fitted with a
stirring bar, ester 32 (0.84g, 1.62 mmol) were dissoved in 10 mL THF, then 40 mL
aqueous 1 N HCl was added at rt. The reaction mixture was stirred at rt, and progress was
monitored by ESI-MS. After 4 days, reaction was completed. Reaction mixture was
killed with NaHCO3 solution, and saturated with NaCl, extracted with EtOAc (3 x 80mL).
The combined organic extracts were dried over Na2SO4, filtered, the solvent was
removed under reduced pressure. The residue was purified by flash column with solvent
(CH2Cl2 : MeOH =10:1), Collect white solid product 33, 260 mg (41% yield). Rf=0.26
(CH2Cl2 : MeOH =10:1), MS: [M+Na]+=418. 1H NMR (300 MHz, DMSO) 0.80 (t,
J=7.5 Hz, 3H), 1.37 - 1.44 (m, 2H), 1.71 (d, J=13.80 Hz, 1H), 1.87 -1.995 (m, 3H), 3.02
(m, 2H), 3.57 (m, 1H), 4.06 (s, 1H), 5.03 (s, 1H), 5.24(dt, J=4.0, 12.3 Hz, 1H), 5.57 (s,
1H), 5.65 (s, 1H), 6.23 (d, J=16 Hz, 1H), 6.76 (d, J=8.1 Hz, 1H), 7.01 (d, J=8.1 Hz, 1H),
7.03 (s, 1H), 7.50 (d, J=16 Hz, 1H), 7.73 (t, J=6.0 Hz, 1H), 9.14 (s, 1H), 9.56 (s, 1H).
Anal. (C19H25NO8. 0.5H2O) calculated: C, 56.79; H, 6.84; N, 3.40. Found: C, 56.63; H,
6.63; N, 3.21.
8-Hydroxy-4-phenyl-3,5,10-trioxa-tricyclo[6.2.1.02,6]undecan-9-one (34). In a
200 mL round-bottom flask fitted with a stirring bar, reflux condenser, Dean-Stark trap,
and argon inlet, A mixture of quinic acid 1 (5.0g, 26.1 mmol), p-totuenesulfonic acid
monohydrate (0.2g), benzaldehyde (4 mL, 39 mMol), and benzene (100 mL) was heated
to reflux for overnight. The reaction mixture was cooled down, and solvent was removed
under reduced pressure. Residue was purified by flash column with solvent mixture of
Hex : EtOAc(1/1, v/v). Collected product 34 as oil that solidified on standing, 6.2g (91%
yield). Rf=0.2 (EtoAC: Hex=1:1). MS: [M+Na]+=285. 1H NMR (CDCl3)  2.42 – 2.53
(m, 4H), 2.82 (d, J=12.0 Hz, 1H), 4.40-4.43 (m, 1H), 4.55-4.60 (m, 1H), 4.84-4.87 (m,
1H), 5.79 (s, 1H), 7.40-7.53 (m, 5H).
Benzoic acid 3-bromo-1-hydroxy-7-oxo-6-oxa-bicyclo[3.2.1]oct-4-yl ester (35).
In a 200 mL round-bottom flask fitted with a stirring bar, reflux condenser, and argon
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inlet, A mixture of compound 34 (2.0g, 7.63 mmol), NBS (1.42g, 7.98 mmol), AIBN
(0.01g), and benzene (120 mL) was heated to reflux for 1 hr under argon. The reaction
mixture was cooled down, and solvent was removed under reduced pressure. Residue was
dissolved in EtOAc, washed with saturated NaHCO3 aqueous solution, collected organic
phase. Rough compound was purified by flash column with solvent mixture of CH2Cl2:
EtOAc (98/2, v/v). Collected product 35 as white solid, 2.2g (85% yield). Rf=0.4 (EtOAc:
CH2Cl2=2:98). MS: [M+Na]+=363. 1H NMR (CDCl3)  2.22 – 2.63 (m, 3H), 2.772.85(m, 2H), 4.50 (d, J=6.6, 1H), 5.03-5.07 (m, 1H), 5.70 (s, 1H), 7.48-7.54 (m, 2H),
7.63-7.68 (m, 1H), 8.03 (d, J=9.0 Hz, 2H).
Benzoic acid 1-(tert-butyl-dimethyl-silanyloxy)-7-oxo-6-oxa-bicyclo[3.2.1]oct2-en-4-yl ester (36). In a 100 mL round-bottom flask fitted with a stirring bar, reflux
condenser, and argon inlet, A mixture of compound 35 (1.85g, 5.44 mmol), DBU (2.4
mL, 16.1 mmol), tert-butyldimethylsilyl chloride (1.12 g, 7.43 mmol), and acetonitrile
(50 mL) was heated to reflux for overnight under argon. The reaction mixture was cooled
down, and solvent was removed under reduced pressure. Residue was purified by flash
column. Collected product 36 as white solid, 1.42g (70% yield). MS: [M+Na]+=397. 1H
NMR (CDCl3)  0.19 (s, 3H), 0.23 (s, 3H), 0.95(s, 9H), 2.42 (d, J=11.0, 1H), 2.50-2.54
(m, 1H), 4.84 (t, J=2.5 Hz, 1H), 5.52 (t, J=1.8 Hz, 1H), 5.86 (dt, J=10.0, 1.8 Hz, 1H),
6.29 (d, J=10.0 Hz, 1H), 7.48 (t, J=7.5 Hz, 2H), 7.62 (t, J=7.5 Hz, 1H), 8.05 (d, J=7.5 Hz,
2H).
1-(tert-Butyl-dimethyl-silanyloxy)-4,5-dihydroxy-cyclohex-2-enecarboxylic
acid propylamide (37). In a 50 mL round-bottom flask fitted with a stirring bar, reflux
condenser, and argon inlet, A mixture of compound 36 (1.30g, 3.48 mmol), and
propylamine (2.60 mL, 1.85g, 31.28 mmol) were combined, then glacial acetic acid (0.60
mL, 0.63 g, 10.43 mmol) was added. The solution was warmed to 85C in oil bath for 60
min under argon. The reaction mixture was cooled down, and solvent was removed
under reduced pressure. Residue was purified by flash column with solvent EtOAc:
Hex=4:1. Collected product 37 as white solid, 0.52 g (45% yield). MS: [M+H]+=330.
Rf=0.17 (EtOAc: Hex=4:1). 1H NMR (DMSO)  0.05(s, 3H), 0.07 (s, 3H), 0.82 (t, J=7.5
Hz, 3H), 0.85(s, 9H), 1.37-1.47 (m, 2H), 1.69 (t, J=12.6, 1H), 1.85-1.91(m, 1H), 2.963.12(m, 2H), 3.57-3.65 (m, 1H), 3.75 – 3.79 (m, 1H), 4.92 (d, J=4.8 Hz, 1H), 5.07 (d,
J=4.8 Hz, 1H), 5.56 (d, J=10.0 Hz, 1H), 5.69 (dd, J=10.0, 1.8 Hz, 1H), 7.21 (t, J=3.0 Hz,
1H).
1,4,5-Trihydroxy-cyclohex-2-enecarboxylic acid propylamide (38). In a 100
mL round-bottom flask fitted with a stirring bar, compound 37 (0.42g, 1.28 mmol) was
dissolved in 50 mL THF under ice bath, then 1 M solution of TBAF (2.0 mL, 2.0 mmol)
was added. The solution was stirred for 1 hr at rt. The solvent was removed under
reduced pressure. Residue was dissolved in methanol, the solution went through
DOWEX 50W *8-200 strongly acidic cation exchanger column to remove TBAF.
Product was further purified by flash column with solvent CH2Cl2: MeOH=96: 4.
Collected product 38, 0.15 g (50% yield). MS: [M+Na]+=238. Rf=0.15 (CH2Cl2: MeOH
=96:4). 1H NMR (DMSO)  0.81 (t, J=7.5 Hz, 3H), 1.37-1.45 (m, 2H), 1.69-1.72(m,
1H), 1.87(t, J=12.3, 1H), 2.96-3.05(m, 2H), 3.57-3.65 (m, 1H), 3.73 – 3.79 (m, 1H), 4.8
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(d, J=6.1 Hz, 1H), 5.0 (d, J=4.8 Hz, 1H), 5.37 (dt, J=10.0, 1.8 Hz, 1H), 5.61 (d, J=1.8 Hz,
1H), 5.64 (s, 1H), 7.78 (t, J=6.0 Hz, 1H). Anal. (C10H17NO4.0.5H2O) calculated: C, 53.56;
H, 8.09; N, 6.25. Found: C, 53.75; H, 8.17; N, 5.93.
3.4.2 Biology
All chemicals and solvents were purchased from Sigma Aldrich Chemical Co. (St.
Louis, MO) if not specified, and were used without any further purification. TNF-alpha
was purchased from Invitrogen (Carlsbad, CA). Great EscAPe SEAP Chemilumi Kit was
purchase from Clontech Lab, Inc. (Mountain View, CA).
3.4.2.1 A549SN cell line and culture
A549 cells (ATCC), which are a human lung adenocarcinoma cell line
representative of alveolar type II epithelium, were maintained in a 5% CO2 incubator at
37C using BME (Cellgrow) supplemented with 10% heat-inactivated fetal calf serum,
2mM L-glutamine (Gibco), 100U/mL penicillin-100 g/mL streptomycin (Gibco). The
plasmid NF-B-SEAP-ntp was cloned.117 For NF-κB transcription activity testing, A549
cells were transfected with NF-B-SEAP-ntp plasmid, this is the A549SN cell line.
3.4.2.2 NF-B activity – A549SN cell SEAP method
Day1: Plate NF-κB cells: (1) Plate NF-κB_SEAP A549 cells, 6.0x104 cells/well
in three 24 well plates, 1000 L DMEM complete medium: 10% heat inactivated FBS,
2mM L-Glu, 100U/mL or 100 g/mL Penn/Strep, 500 g/mL G418. (2) Incubate at 37°C
incubator with 5% CO2. Day2 : Treat cells with drugs: Cells are all alive, not confluent
(~25-40%). Treat cells with QA=1M, or other compounds @ 1 M (990 L 1% FBS
DMEM + 10 l (10/500) PBS diluted compounds from 5mM in DMSO), + 10 ng/mL
TNFα, for 24 hrs. Day 3: Measure SEAP activity: 24 h later, take out 50L medium.
Store at –20C. Use Clontech “Great EscAPe SEAP Chemiluminescence Detection Kit”
(Cat# K2041-1) to measure luminescence through microplate luninometer (Packard HT
microplate reader). Measure 1 second for once at RT. Cells left in plate were lysed in 250
l lysis buffer (10mMK2HPO4; 1mMKH2PO4; 1%Triton X100; 1mMDTT) for protein
quantification (Pierce BCA Protein Assay Kit, Microplate Procedure) and SEAP activity
was normalized to the total protein content.
3.4.2.3 Anti-oxidant activity test method
The DPPH and all standard antioxidant compounds including trolox were
dissolved in 50% acetone. The DPPH stock solution at a concentration of 0.625 mM was
prepared monthly and kept at 4°C in dark. The 0.208 mM fresh DPPH working solution
was made daily by further diluting the stock solution in 50% acetone for each test. Stock
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solutions of CA, CGA, AA and compound 3 were prepared in 50% acetone at
concentrations of 10 mM, respectively, and stored at 4°C. A series of working solutions
were made by appropriate dilutions of the above standard phenolic acid stock solutions
with 50% acetone.
3.4.2.4 Conventional colorimetric analysis
The conventional colorimetric DPPH scavenging capacity assay was performed
according to a previously described laboratory protocol.116 Briefly, an aliquot of 500 L
of different concentrations of sample extracts in 50% acetone was added to 500 L of
0.208 mM DPPH solution. The initial concentration was 0.104 mM for DPPH in all
reaction mixtures. Each mixture was vortexed for a few seconds and test immediately.
The absorbance (A) of each reaction mixture at 515 nm was measured against a blank of
50% acetone using a UV-visible spectrometer. The level of DPPH remaining for each
reaction time was calculated as: % DPPH remaining=(A sample-t / A control) x 100.
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CHAPTER 4. DETERMINATION OF QUINIC ACID AMIDES IN RAT
PLASMA BY LC/MS/MS WITH A HYDROPHILIC INTERACTION LIQUID
CHROMATOGRAPHY COLUMN
4.1 Introduction
The interest in development of natural sources of anti-inflammatory activity has
exploded in recent years. Quinic acid (QA) is a natural compound found widely in plants.
Recently, QA has been identified as an active inflammatory ingredient in hot water
extracts of the herbal Cat’s claw (e.g., C-MED-100), and shown to enhance immune cell
response and DNA repair in humans.3-5 Unfortunately, QA is utilized by gastrointestinal
bacteria as a carbon source for aromatic acid synthesis. Consequently, only a small
fraction of QA is absorbed after oral administration of QA.27 Our group has focused on
the discovery and development of stable QA derivatives. We have identified water
soluble QA amide KZ-41(Compound 3) which possess potent anti-inflammatory
activity.118,119 To study the pre-clinical pharmacokinetic properties of KZ-41, an
analytical method is required for determination of the concentration of KZ-41 in preclinical samples.
There is no determination method of quinic acid amides, such as KZ-41 in the
literature. Several methods of determination of QA in plants and food have been
described.125-127 The reverse phase column (C18 or C8) were used in the HPLC methods
reported. Because QA is water soluble, the mobile phase used in RP column consisted of
very high percentage of water, and re-equilibrated with 99% ACN in actually
application.125 Both QA and KZ-41 are water soluble and high polar. The determination
of polar compounds in biological fluids is very efficient by using hydrophilic interaction
liquid chromatography–tandem mass spectrometry (HILIC–MS/MS) method.128-130 The
advantages of ESI-MS detection in conjunction with HILIC mode separations are
obvious: better separation with high organic phase and high sensitivity.131,132 UV
detection could be much simpler, but the sensitivity for QA and KZ-41 were worse due to
their lack of UV absorption function group.
This chapter has developed and validated a rapid, robust and sensitive HILICMSMS method which employs protein precipitation for the quantitative analysis of QA
amide KZ-41 in rat plasma. It has lower limit of quantitation (LLOQ) of 0.5 ng /mL.
4.2 Experimental
4.2.1 Material and Reagents Synthesis of Quinic Acid Amides
KZ-41 and internal standard (IS) (Figure 4-1) were synthesized in our medicinal
chemistry Lab. Methanol, acetonitrile, acetone, and water (HPLC grade), were purchased
from Sigma-Aldrich (St Louis, MO, USA) and the other chemicals were of HPLC grade
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Figure 4-1. Chemical structure of quinic acid, KZ-41 and IS.
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or the highest quality available. Drug-free rat plasma were obtained from Pelfreez
Biologicals (Rogers, AR, USA).
4.2.2 Preparation of Calibration Standards and Quality Control Samples Biology Testing
of Quinic Acid Amides
KZ-41 stock solution (1mg/mL) was prepared in acetonitrile. Serial working
standard solutions of KZ-41 were prepared by further diluting each primary solution with
acetonitrile to obtain desired concentrations. The drug-free rat plasma was spiked with
KZ-41 and IS solution, and protein precipitated to prepare rat plasma solution.
The nominal rat plasma calibration standards of KZ-41 (0.5, 1.0, 5.0, 10.0, 50.0, 100.0,
and 500.0 ng/mL) were prepared as above. The quality control samples were chosen at
concentration levels (5.0, 25.0, and 125.0 ng/mL).
An IS stock solution (1mg/mL) was prepared in methanol. The IS working
solution was diluted with methanol to a final concentration of 10 ng/mL. All solutions
were stored at −20C.
4.2.3 Sample Processing
Rat plasma samples were processed by protein precipitation. A 50 μl volume of
plasma sample was diluted with 150 μl of methanol with IS (10 ng/mL). The samples
were vortexed vigorously for 5 min, refrigerated sample for 2 hrs, and the mixture was
centrifuged for 15 min at 10 000 g. Supernatant aliquots of 100 μl were transferred to
vials and evaporated to dry by TurboVap LV concentration workstation (Caliper Life
sciences, Hopkinton, MA) at 30C under nitrogen. The residues were reconstituted to 200
μl with pure acetonitrile and vortex-mixed for 2 min. Aliquot of 20 μl was injected into
LC-MS/MS for analysis.
4.2.4 Instrumentation
4.2.4.1 Chromatographic conditions
Chromatographic separation of analyte was carried out using Shimadzu
(Columbia, MD) LC-10ADvp pumps with a Leap (Carrboro, NC) CTC PAL autosampler.
The separation was performed on a PolyHYDROXYETHYL ATM HILIC column (5 μm,
100 x 2.1 mm, 100 Å, The Nest Group, Inc., South borough, MA, USA). The mobile
phase consisted of eluent A (water) and eluent B (acetonitrile), and separation achieved
using a gradient program of 0 min: 15% A; 4 min: 40% A; 4.5 min: 15% A, and the total
analytical run time was 5.5 min. The flow rate was 0.2 mL/min with the column at
ambient temperature.
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4.2.4.2 Mass spectrometric conditions
An API 4000 Q TRAP mass spectrometer equipped with an electrospray ion
source (Applied Biosystems Sciex, Foster city, CA) operated in negative-ion mode was
used for MS detection. Quantitation was performed using MRM mode to study parent→
product ion transitions for KZ-41 (232 → 178) and IS (272 → 218) with unit resolution.
Source dependent parameters optimized were gas 1 (nebulizer gas): 30 psi, gas 2 (heater
gas): 40 psi, ion spray voltage (ISV): -4500 V, temperature [(transmission electron
microscope (TEM)]: 700°C. Compound dependent parameters were declustering
potential (DP), entrance potential (EP), collision energy (CE), cell exit potential (CXP).
DP: -50 V, CE: -28 V, EP: -10 V, CXP: -15 V were set for KZ-41, and DP: -60 V, CE: 32 V, EP: -10 V,CXP: -15 V were set for IS. Focusing potential (FP) was 400 V for both
analyte and IS. Nitrogen was used as collision-activated dissociation (CAD) gas and was
set at 6 psi. Quadrupole 1 and quadrupole 3 were maintained at unit resolution and dwell
time was set at 250 ms.
4.2.4.3 Data processing and quantification
Mass spectrometric data acquisition and data analysis were done with the Analyst
Version 1.5. Software (Applied Biosystems). A weighted 1/x linear regression was used
to generate calibration curve from standards and calculate the concentrations of quality
control and unknown samples. Equation of the standard curve: y=mx + b, where ‘y’ is the
peak area ratio of the analyte to IS, ‘x’ is the theoretical concentration of the analyte
divided by the theoretical concentration of IS, ‘m’ is the slope and ‘b’ is the
intercept of the regression line.
4.2.5 Method Validation
4.2.5.1 Linearity, accuracy and precision
Rat plasma calibration standards were analyzed in three separate analytical runs.
The peak areas generated by KZ-41 and IS were used to calculate their area ratios. The
calibration curves were plotted by weighted 1/x linear regression analysis of
concentrations of KZ-41 versus the peak ratios of KZ-41 and IS.
The intra-batch precision and accuracy were assessed by determinations of KZ-41
in rat plasma at nominal concentrations of 5.0, 25.0, and 125.0 ng/mL, on the same day.
The inter-batch precision and accuracy were carried out by analyzing the same samples
on three different days. Five replicates of each sample were analyzed together with a set
of calibration standards, independently prepared from the control samples, in five
analytical runs. The CV (%) values of measured concentrations were used to show the
precision of the method. The deviation of the mean measured concentrations away from
the corresponding nominal concentration served as a measure of accuracy.
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4.2.5.2 Matrix effect and recovery
Matrix effect and recovery were evaluated according to a published literature.133
Briefly, matrix effect was determined by comparing the analytical response of the
standards spiked into plasma extracts (Solution B) with that of the net standard solutions
(Solution A). The loss of signal represents the ion suppression. The extraction recovery
of KZ-41 from rat plasma was determined by comparing the analytical response of
processed quality control samples (Solution C) with that of blank net plasma extracts
spiked with standard working solutions (Solution B). They are expressed as: matrix effect
(ME%)=(B/A)*100; recovery rate (RR%)=(C/B)*100. These experiments were
performed in triplicate at concentration level 5.0, 25.0, and 125.0 ng/mL.
4.2.5.3 Stability
Storage stability tests were performed with quality control (QC) samples
subjected to different storage conditions (4°C or at 25°C for 48 h). The stability was
calculated by comparing injected freshly prepared QC samples with re-injected samples
48 h later. Five replicates were analyzed with each sample at each concentration. Three
concentration levels (5.0, 25.0 and 125.0 ng/mL) were studied. The storage stability of
both KZ-41 and IS in the working solution and in the processed extracts was investigated.
4.3 Results and Discussion
4.3.1 Optimization of Sample Preparation Procedure
Protein precipitation is a valid and fast rat plasma sample preparation procedure.
The commonly used solvent is acetonitrile. We started with acetonitrile as plasma splash
solvent (150 l organic solvent into 50 l plasma), the recovery rate was poor. Then
other organic solvents (methanol, acetone, and chloroform) were tested. We found
methanol provided a good protein precipitation and drug extraction recovery. Methanol
was selected as plasma splash organic solvent.
4.3.2 Optimization of Chromatography Condition
Good chromatography separation with sharp peak shape will ensure high
selectivity, specificity and sensitivity of the analytical method. This optimization will be
achieved by good matching within analyte, column, and mobile phases. KZ-41 is an
amide, neutral in acidity, and water soluble (LogP=-2.03). We tested it on a C8 reversephase symmetry (3.5 μm, 2.1 × 50 mm, 100 Å) column, 95% aqueous phase in mobile
phase was needed to obtain 2 min retention time, and the peak shape was distorted.
Furthermore, too much aqueous reduce the sensitivity of MS detection, and the stability
of the C8 column. When KZ-41 was separated on a PolyHYDROXYETHYL ATM HILIC
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column (5 μM, 100 x 2.1 mm, 100 Å, The Nest Group, Inc., Southborough, MA, USA),
with 85% acetonitrile in mobile phase (acetonitrile and water), this amide had about 3
min retention time with good peak shape (Figure 4-2). The higher percentage of organic
phase improved the sensitivity of MS detection. Several compounds from KZ-41
chemical library were investigated to find a suitable IS, a structurally similar analog was
found to be the most appropriate for this study. The structures of quinic acid, KZ-41, and
IS were shown in Figure 4-1.
4.3.3 Optimization of MS Instrumentation
MS instrument parameters for determination each compound were optimized by
directly infusion each compound (1 μg/mL acetonitrile solution) into the mass
spectrometer at a flow rate of 600 μl/h. On the negative full scan mass spectra, the deprotonated molecular ions [M - H]- of KZ-41 and IS were observed at a mass to charge
ratio (m/z) of 231.7 and 271.9, respectively. The product ion scan resulted in a major
fragment at m/z 177.8 for KZ-41 and m/z 217.9 for IS (Figure 4-3). The fragments were
the products of parent molecules by lost three water molecules (mass=18*3). These
MRM ion pair selections contributed to the compound specificity of the MS method. The
CE and collision CXP were optimized in order to obtain the best product ion/precursor
ion intensity ratio. The mass spectrometry detection MRM ion pairs for KZ-41 and IS
were selected as 232/178 and 272/218 at unit resolution, respectively. Parameters
including ionization voltage, focusing and DP, flow of curtain and nebulizer gas were
further investigated in order to obtain the maximum intensity as a HILIC/MS/MS
analysis method.
4.3.4 Linearity, Accuracy and Precision
A linear dynamic range was obtained over the concentration range from 0.5 to
500 ng /mL (Figure 4-4). The standard curve equation is y=0.0059x + 0.0154. The
correlation coefficient (r2) is greater than 0.999.
The intra- and inter-day accuracy and precision are presented in Table 4-1. The
intra-day accuracy was 112.67%, 98.89%, 98.06% at concentrations of 5.0, 25.0, and
125.0 ng/mL respectively. They are all within the accepted deviation range 85% to 115%.
The CV (%) value is also within accepted range.
4.3.5 Specificity and Selectivity
MRM chromatograms of blank, KZ-41, IS and QC samples were showed in
Figure 4-2. LC/MS/MS system with MRM mode provides high selectivity and
specificity. The LC separation selectivity and specificity was good, there was no peaks
that co-eluted with either KZ-41 or the IS, and each analyte had specific retention time
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Figure 4-2. Representative HILIC-MS MRM chromatograms of KZ-41 and IS in
extraction from rat plasma. The separation was performed on a PolyHYDROXYETHYL
HILIC column with 85% acetonitrile in water as the mobile phase. The flow rate was 0.2
mL/min. Detection was performed using triple quad mass spectrometer in negative
MRM mode.
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Figure 4-3. Product mass spectra of KZ-41 and IS. Upper spectrum. KZ-41, parent ion
[M-H]=232, dominated daughter ions: 214, 196, 178. Lower spectrum. IS, parent ion [MH]=272, dominated daughter ions: 254, 236, 218.
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Figure 4-4. Representative standard curve of KZ-41 in rat plasma. The standard curve
equation is y=0.0059x + 0.0154. The correlation coefficient (r2) is greater than 0.999 over
the concentration range of 0.5 to 500 ng /mL.

57

Table 4-1. Intra- and inter-day accuracy and precision of KZ-41 in rat plasma.
Time

Nominal
concentration
(ng/mL)

Found
concentration
(ng/mL)

Accuracy (%)a CV (%)b

Intra-day (n=5)

5.0
25.0
125.0

5.63
24.72
122.57

112.67
98.89
98.06

14.08
5.38
3.75

Inter-day (n=3)

5.0
25.0
125.0

5.36
24.12
123.15

107.20
96.48
98.52

11.20
5.80
3.30

a

Accuracy (%) is calculated as mean found concentrations over nominal concentration x
100%.
b
CV (%) is calculated as standard deviation of found concentrations over nominal
concentration x 100%.
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(Figure 4-2). MRM ion pairs were parent ions with moiety-specific fragment ions, there
was no mass transition interference from rat plasma with either of the compounds.
4.3.6 Matrix Effect and Recovery
In this study, the values of matrix effect were 79.4% and 81.3% for KZ-41 and IS,
respectively, which meant the biological matrix had similar effect on the ionization of
KZ-41and IS. Extraction recoveries for KZ-41 and the IS were 100.9% and 99.2%,
respectively. Only a negligible carryover effect (about 0.1%) was observed after injection
of a blank plasma extract following injection of the upper calibration standard.
4.3.7 Stability
The result showed both KZ-41 and IS in the working solution and in the
processed extracts were stable over 48 h storage (4°C or at 25°C for 48 h). KZ-41 and IS
did not show any significant degradation after protein plasma precipitation even after 48
hr. This suggests that plasma protein precipitation can be conveniently performed within
2 days of the LC-MS/MS measurement analysis. In the freeze/thaw investigations and
long-term stability experiments, the observed maximum degradation was within 20% and
fulfilled the acceptance criteria.
4.4 Conclusions
A robust and sensitive HILIC-MS/MS method for the analysis of KZ-41 in rat
plasma has been developed and validated. This assay used protein precipitation method
for sample preparation, has a lower limit of detection of 0.5 ng /mL. The standard curve
equation is y=0.0059x + 0.0154. The correlation coefficient (r2) is greater than 0.999 over
the concentration range of 0.5 to 500 ng /mL. It is novel and useful for the
pharmacokinetic studies of KZ-41.
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CHAPTER 5. PHARMACOKENETICS AND BIOAVAILABILITY OF NOVEL
ANTI-INFLAMMATORY AGENT KZ-41
5.1 Introduction
Many interests have been raised in development of natural products or modified
products having anti-inflammatory activity in recent years. Quinic acid (QA) is a natural
compound found widely in plants.8-10 Recently, QA has been identified as an active
ingredient in hot water extracts of the herbal Cat’s claw (e.g., C-MED-100), and shown
to enhance immune cell response and DNA repair in humans.3-5 In particular, such
extracts have been found to have various anti-inflammatory effects such as inhibition of
the production of the inflammatory cytokine TNF, scavenges free radicals45 and the
activation of the central transcription factor nuclear factor κB (NF-κB).46-49 Unfortunately,
QA is utilized by microorganisms and plants through the shikimate biosynthetic pathway
leading to aromatic amino acids phenylalanine, tyrosine, and tryptophan.16,19,20,134,135 In
1967, a QA oxidizing enzyme produced by acetic acid bacteria was discovered
demonstrating that bacteria could catabolize QA.25 Subsequently, the QA catabolic
pathway was described as a result of characterization of fungal mutants with lesions in
genes encoding biosynthetic shikimate pathway enzymes.26 Bacteria and fungi utilize
QA as a growth substrate and thus express an abundance of the aforementioned enzymes
involved in QA transformation. High levels of QA catabolizing enzymes in gut bacteria is
consistent with the finding that less than 10% of an orally administered dose QA is
recovered in rats.27
In short, rapid degradation by gut flora potentially limits the oral effectiveness of
current quinic acid preparations. Our study group has focused to discover new antiinflammatory agents that will be orally active based on the quinic acid structure. We have
identified water soluble QA amide KZ-41 which possess potent anti-inflammatory
activity.118,119 There are no biopharmaceutical and pharmaceutics data available for this
compound to establish the dosing for in vivo animal study. This study was conducted to
investigate the bacterial stability, and absorption, distribution, metabolism and
elimination of KZ-41 in rat after intravenous and oral administration.
5.2 Experimental
5.2.1 Material and Reagents
KZ-41 and internal standard (IS) were synthesized in our medicinal chemistry
Lab. Methanol, acetonitrile, acetone, and water (HPLC grade), were purchased from
Sigma-Aldrich (St Louis, MO, USA) and the other chemicals were of HPLC grade or the
highest quality available. Drug-free rat plasma was obtained from Pelfreez Biologicals
(Rogers, AR, USA).
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5.2.2 Microsomal Stability
Microsomal metabolic stability of KZ-41 was assessed in Pooled IGS SpragueDawley Rat Liver Microsomes (Xenotech, LLC, Lenexa, Kansas) preparations by
monitoring disappearance of the parent compound over an incubation period of 90
minutes. The concentration change of intact parent compound in the samples was
estimated by comparing analyte concentrations before and after incubation using LCMS/MS assay. The detailed procedure is described in the following. The stock solution
(10 mM stock in methanol) was diluted in PBS buffer (50 mM, pH 7.4) to make 500 µM
working solution. Test compounds were incubated at a final concentration of 5.0 µM. A
concentration of 50.0 µM was utilized to allow for detection of possible minor
metabolites. Rat liver microsomes were utilized at a final concentration of 1.0 mg/mL.
Reactions mixture were prepared by adding 25 µl of microsomal sprotein solution
(20mg/mL) to 50 µl test compound (500 µM) and 425 µl of NADPH regenerating
system (NRS) “master mix” solution. The combined components, with the exception of
the microsomes, were preincubated at 37°C for 10 min, after which the microsomes were
added. The mixture was incubated in a water bath at 37ºC. Deactivated microsome
solution was used as negative control. The NRS “master mix” is a solution of glucose 6phosphate dehydrogenase, NADP+, MgCl2, and glucose 6-phosphate, prepared per
manufacturer’s instructions (BD Biosciences, Waltham, MA). Each 5.0 mL stock of
NRS “master mix” solution contains 3.8 mL H20, 1.0 mL solution “A” (Cat. #451220),
and 0.2 mL solution “B” (Cat. #451200).
At each time point (0, 45 and 90 minutes), 100 µl of reaction was removed and
the reaction was terminated by addition of 100 µL of acetonitrile containing internal
standard IS (150 ng/mL). Samples were then centrifuged at 10,000 rpm for 10 minutes at
4°C to remove debris and precipitated protein. Approximately 150 µl of supernatant was
subsequently transferred to a new sample vial for analysis.
5.2.3 Plasma Protein Binding
Plasma protein binding of KZ-41 was determined by using rapid equilibrium
dialysis. The RED device for rapid equilibrium dialysis was obtained from Pierce
Biotechnology Inc (Rockford, IL). The experimental procedure was followed to the
manual protocol with optimization. Briefly, biologically relevant concentrations of test
compound were prepared (low, middle and high) in rat plasma. The RED inserts were
placed in the base plate. 300 μL of the plasma sample was placed in the sample chamber
and 500 μL of dialysis buffer, pH 7.4 in the buffer chamber. The chambers were covered
with a seal and incubated at 37ºC for 4-6 hours at approximately 100 rpm on an orbital
shaker. At the end of incubation, remove seal and confirm volume of the sample
chamber. Minimal to no volume change should have occurred. Aliquots of plasma and
buffer were used to determine the drug concentration using an LC-MS/MS assay. Pipette
50 μL each of post-dialysis samples from the buffer and the plasma chambers into
separate microcentrifuge tubes. Add 50 μL of plasma to the buffer samples, and an equal
volume of PBS to the collected plasma samples. Add 100 μL of precipitation Methanol
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to precipitate protein and release compound. Vortex and incubate 30 minutes on ice.
Centrifuge for 10 minutes at 13,000-15,000 × g. Transfer supernatant to a vial, dry the
supernatant under nitrogen, and reconstitute to 200 μL with acetonitrile before
LC/MS/MS. Determine the concentration of test compound in the buffer and plasma
chambers from peak areas relative to the internal standard. Calculate the percentage of
the test compound bound as follows:
% Free=(Concentration buffer chamber/Concentration plasma chamber) × 100%
% Bound=100% - % Free
5.2.4 Bacterial Stability
Bacteria Gluconobacter oxydans was selected to test the bacterial stability of QA
analogs.30,31 The log growth phase in which this bacterial strain has the most active
growth, was obtained by plotting the growth curve of this bacterial. The growth curve of
this bacteria strain was obtained by taking OD readings generally at 0, 0.5, 1, 2, 4, 8, 12,
and 24 hours when bacterial is cultured. Then plot the log OD versus time and find the
linear portion of the graph which is the log growth phase of this bacterial. Gluconobacter
oxydans was incubated in mannitol media at 26C and 150 rpm, and used to test the
stability of QA analogs when it was in the log growth phase. Test was divided into three
groups: negative control (QA in autoclaved bacterial media), positive control (QA in
active bacterial media), and treatment (KZ-41 in active bacterial media). Compounds
were dissolved in fresh culture media. 200 l test solution (2mg/mL) was added into 3
mL bacterial media in a 6 well plate. Samples were taken at different time points after
treatment. Sampling procedure: removed 200uL sample from each well and put into
labeled tubes, quenched sample with 300uL of methanol. Between samplings, plate was
placed on C24 Incubator Shaker (New Brunswick Scientific, Edison, NJ) at 26C and 150
rpm. Samples were store at -80C for future use.
5.2.5 Pharmacokinetic Studies in Rats
All animal procedures used in this research were approved by the University of
Tennessee Animal Care and Use Committee. Pre-cannulated Sprague-Dawley male rats
(200 -300 g, jugular vein alone for oral study and jugular vein and femoral vein for
intravenous study) were obtained from Harlan Bioscience (Indianapolis, IN). Animals
were fed a normal laboratory diet, allowed ad libitum access to water and maintained on a
12-hr light-dark cycle (25ºC). The catheter was exteriorized between the shoulder blades
to ensure the catheter remains in place over the sampling interval. Catheter patency was
maintained with heparin glycerol solution (100 IU heparin/mL in 75% glycerol saline
solution). Groups of animals (n=6) received a dose (10 mg/kg) of the compound of KZ41 via the oral or intravenous route. For oral administrations, the animals were fasted
overnight and until 4 hr after administration of test compound. Blood samples (200 to
300 uL) were withdrawn from the jugular vein catheter pre-dose and at regular intervals
after dosing (5, 15, 30, 45 minutes and 1, 2, 4, 8, 12, and 24 hrs). An equal volume of
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sterile saline solution will be administered via the jugular vein catheter after each blood
collection. All experiments will be performed on un-restrained animals. A maximum of
twelve blood samples, representing no more than 2% of the body weight in blood volume,
were taken from individual animals. Blood was transferred into Microtainer® brand tubes
with lithium heparin (BD, Franklin Lakes, NJ). Plasma was separated immediately by
centrifugation (3000g for 2 min at 4ºC). Urine and fecal samples were pooled and
collected up to 24 hr respectively. All samples were stored at -80°C until future analysis.
5.2.6 Analytical Methods
A LC-MS/MS method was developed to quantitate KZ-41 concentration in rat
plasma. This method was validated and published separately. Chromatographic
separation of analyte was carried out using Shimadzu (Columbia, MD) LC-10ADvp
pumps with a Leap (Carrboro, NC) CTC PAL autosampler. The separation was
performed on a PolyHYDROXYETHYL ATM HILIC column (5 μM, 100 x 2.1 mm, 100
Å, The Nest Group, Inc., South borough, MA, USA). The mobile phase consisted of
eluent A (water) and eluent B (acetonitrile), and separation achieved using a gradient
program of 0 min: 15% A; 4 min: 40% A; 4.5 min: 15% A, and the total analytical run
time was 5.5 min. The flow rate was 0.2 mL/min with the column at ambient temperature.
An API 4000 Q TRAP mass spectrometer equipped with an electrospray ion source
(Applied Biosystems Sciex, Foster city, CA) operated in negative-ion mode was used for
MS detection. Quantitation was performed using MRM mode to study parent→ product
ion transitions for KZ-41 (232 → 178) and IS (272 → 218) with unit resolution. Source
dependent parameters optimized were gas 1 (nebuliser gas): 30 psi, gas 2 (heater gas): 40
psi, ion spray voltage (ISV): -4500 V, temperature [(transmission electron microscope
(TEM)]: 700°C. Compound dependent parameters were declustering potential (DP),
entrance potential (EP), collision energy (CE), cell exit potential (CXP). DP: -50 V, CE:
-28 V, EP: -10 V, CXP: -15 V were set for KZ-41, and DP: -60 V, CE: -32 V, EP: -10
V,CXP: -15 V were set for IS. Focusing potential (FP) was 400 V for both analyte and IS.
Nitrogen was used as collision-activated dissociation (CAD) gas and was set at 6 psi.
Quadrupole 1 and quadrupole 3 were maintained at unit resolution and dwell time was set
at 250 ms.
Rat plasma samples were processed by protein precipitation. A 50 μl volume of
plasma sample was diluted with 150 μl of methanol with IS (10 ng/mL). The samples
were vortexed vigorously for 5 min, refrigerated sample for 2 hrs, and the mixture was
centrifuged for 15 min at 10 000 g. Supernatant aliquots of 100 μl were transferred to
vials and evaporated to dry by TurboVap LV concentration workstation (Caliper Life
sciences, Hopkinton, MA) under nitrogen at 30C. The residues were reconstituted to 200
μl with pure acetonitrile and vortex-mixed for 2 min. Aliquot of 20 μl was injected into
LC-MS/MS for analysis.
An aliquot, 600 l, of the pooled urine was evaporated to dryness under nitrogen,
200 μl of acetonitrile with IS (10 ng/mL) was added. Approximately 1.8 g of pooled fecal
sample was extracted with 10 mL of methanol for 1 hr in a polypropylene centrifuge tube
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using a rotating mixer. The extract was centrifuged at 4,000g for 10 min. The supernatant
was transferred to a new tube. The pellet was re-extracted as described above and the
supernatants were combined. The extract was evaporated to dryness under a stream of
nitrogen, residue was dissolved in 0.5mL methanol water mixture (50/50 v/v), and
transferred into a 1.8 mL vial. This mixture was evaporated to dryness under nitrogen,
and 200 μl of acetonitrile with IS (10 ng/mL) was added. The samples were vortexed
vigorously for 5 min, and the mixture was centrifuged for 15 min at 10 000 g.
Supernatant aliquots of 20 μl was injected into LC-MS/MS for analysis.
5.2.7 Pharmacokinetic Data Analysis
Plasma concentration-time profiles were analyzed by non-compartmental analysis
using WinNonlin 5.0.1 (Pharsight Corporation, Mountain View, CA). The maximum
plasma concentration (Cmax) observed after oral dosing and the time at which it was
observed (Tmax) were determined by direct inspection of the individual plasma
concentration-time profiles. The terminal half-life (t1/2) was calculated as 0.693 divided
by the terminal phase rate constant λz. The area under the plasma concentration-time
curve from time 0 to infinity (AUCinf) was calculated by the trapezoidal rule with
extrapolation to time infinity. The total plasma clearance (CL) of i.v. KZ-41 was
calculated as the i.v. dose divided by the AUCinf of i.v (CL=Doseiv/AUCinf,iv). Volume of
distribution based on terminal phase (Vz) was calculated as the i.v. dose divided by the
product of AUCinf of i.v and λz (Vz=Doseiv/( λz *AUCinf, iv)). The parameters of oral
dose were calculated same way as iv dose. The relative oral bioavailability (F) was
calculated as F=(AUCinf, oral* Doseiv)/(AUCinf, iv *Doseoral).
Statistical analyses were performed using a two-tailed t test at a 5% level of
significance.
5.3 Results
5.3.1 Pharmacokinetics of KZ-41
The structure of KZ-41 is shown in Figure 5-1. Figure 5-2 shows the plasma
mean concentration – time profile of KZ-41 (n =6) after administration of i.v. and oral
doses at dose of 10 mg / kg. The derived pharmacokinetic parameters is listed in Table
5-1. The total plasma clearance of KZ-41 in rats was 13.8 mL/min/kg (i.v.), or 12.1
mL/min/kg (oral). This moderate clearance indicated the compound would have
reasonable duration in the body. The terminal plasma elimination half-lives was 183 min,
or 3.1 hr. The compound was moderately distributed in the body with volume of
distribution of 3.65 L/kg. The amount of compound excreted unchanged into urine and
feces was approximately 60% of the dose by both routes, this suggested low metabolism
of KZ-41 in the rat body. The oral bioavailability of this compound in rat was about
111%. Theoretically, Bioavailability should not exceed 100%. The result which is over
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Figure 5-1. Chemical structure of quinic acid amide KZ-41.
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Figure 5-2. Rat plasma meanlog concentration – time plot of KZ-41 after a single dose
(10 mg/kg, n=6). The curve without absorption peak is IV dose curve, the curve with a
peak is oral dose curve. Each points represents the mean ±S.D.
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Table 5-1. Key pharmacokinetic parameters of KZ-41 in rats (n=6) calculated by mean
concentrations versus time profile (Dose: 10mg/kg).
Route

Cmax
ng/mL

Tmax
min

AUC
min*ug/mL

T1/2
min

CL
mL/min/kg

IV
PO

15688.7
4591.3

5.0
45.0

722.2
803.1

183.1
147.7

13.8
12.1

p=0.67.
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Vz
mL/kg

F

3654.3
2579.8 1.11

100% may due to experimental error. T-test has been done to compare the AUC of i.v. to
that of oral. The p-value was 0.67. Statistically, bioavailability of KZ-41 in rat was 100%.
Key pharmacokinetic parameters of KZ-41 in individual rat by i.v. and oral
administration were listed in Table 5-2 and Table 5-3 respectively.
5.3.2 Microsomal Metabolic Stability
KZ-41 was metabolically stable when incubated with pooled IGS SpragueDawley rat liver microsomes (Table 5-4.). The parent compound was about 100%
remaining after 90 min incubation, while the positive control (propanolol) was 32%
remaining.
5.3.3 Plasma Protein Binding
The plasma protein binding data of KZ-41 is listed in Table 5-5. The plasma
protein binding was moderate and not concentration dependent over the concentration
range of 50 ng/mL to 5000 ng/mL, with an average of 27.46% bound to plasma proteins.
At concentrations of 50 ng/mL, 500 ng/mL, and 5000ng/mL, the percentage of KZ-41
bound was 21.27%, 28.83%, and 32.29% respectively.
5.3.4 Bacterial Stability
Bacteria Gluconobacter oxydans was unable to utilize KZ-41 as food by
transforming it to another form (Figure 5-3). The parent compound KZ-41 remained
100% unchanged with cultured bacterial over 24 hr. As expected, QA was not stable in
bacterial cultured media, less than 10% unchanged QA remained after one day.
5.4 Discussion
The present study demonstrates that KZ-41 had high oral bioavailability (about
100%). This could be the result of numerous factors, including being stable with gut
microflora, good absorption, slight first-pass metabolism in the intestinal wall and/or in
the liver. First, KZ-41, not like QA, was not growth substrate target by bacteria
Gluconobacter oxydans as we shown in bacterial stability study. It was stable in bacterial
cultured medium. The enzymes responsible for QA transformation are quinate
dehydrogenase (QDH), 3-dehydroquinate dehydratase (DQD), and 3-dehydroshikimate
dehydratase.16, 30, 31 KZ-41 is not the substrate of QDH or DQD, may be the inhibitor of
these enzymes of the bacterial. Further mechanism study is on going. Second, KZ-41 was
well absorbed after oral administration, with a mean Cmax value of 4.59 µg/mL achieved
at 45 min. KZ-41 is a highly water soluble small molecular QA amide, with molecular
weight 233 and negative CLogP 2.03. Therefore, it appears to be permeable through the
gastrointestinal tract. This suggestion is also evidenced by the fact that about 60% of the
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Table 5-2. Key pharmacokinetic parameters of KZ-41 in rats by intravenous
administration (Dose: 10mg/kg).
Animal
1
2
3
4
5
6
Mean
S.D.

Cmax
ng/mL
12760.0
24400.0
24560.0
12320.0
11920.0
8948.0
15818.0
6841.8

Tmax
min
5.0
5.0
5.0
5.0
5.0
5.0
5.0
0.0

AUC
min*ug/mL

T1/2
min

CL
mL/min/kg

637.4
1024.3
1070.2
585.7
530.1
473.4
720.2
259.6

202.2
136.6
147.4
148.8
149.8
131.5
152.7
25.3

15.3
9.7
9.2
16.8
18.6
21.0
15.1
4.8
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Vz
mL/kg
4447
1920
1960
3600
404
3984
3325.5
1106.4

Table 5-3. Key pharmacokinetic parameters of KZ-41 in rats by oral administration
(Dose: 10mg/kg).
Animal
1
2
3
4
5
6
Mean
S.D.

Cmax
ng/mL

Tmax
min

4220.0
4284.0
1540.0
6192.0
11680.0
2668.0
5097.3
3592.1

45.0
45.0
120.0
60.0
45.0
45.0
60.0
30.0

AUC
min*ug/mL
855.6
858.2
303.1
1021.8
1337.0
447.0
803.8
378.3
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T1/2
min
130.8
147.6
301.0
178.4
213.8
130.5
183.7
65.8

CL
mL/min/kg
11.5
11.3
31.5
9.3
7.2
22.0
15.5
9.4

Vz
mL/kg
2164
2412
13677
2390
2230
4136
4501.5
4555.7

F
1.19
1.19
0.42
1.42
1.86
0.62

Table 5-4. KZ-41 rat liver microsomal stability study.

Time (Min)
0
45
90

KZ-41

Positive control

% Remaining SD

% Remaining SD

100.0
109.9
106.5

13.3

100.0
32.1
42.3

9.0

Negative control
% Remaining SD
100.0
104.2
87.9

Positive control (propranolol), Negative control (propranolol with deactivated
microsomes).
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9.3

Table 5-5. KZ-41 protein binding in rat plasma.
Concentration, ng/mL
50
500
5000
Mean

% Bound

% Free drug

21.27
28.83
32.29
27.46

78.73
71.17
67.71
72.54
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Standard deviation (%)
10.01
9.61
7.89
9.17

120

% Remaining

100
80
60
40
KZ-41
Killed Bacteria, QA
QA

20
0
0

5

10

15

20

25

Time (hr)
Figure 5-3. Bacterial stability of KZ-41. The parent compound KZ-41 remained 100%
unchanged with cultured bacteria over 24 hr. As expected, QA was not stable in bacterial
cultured media, less than 10% unchanged QA remained after one day.
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administered dose was excreted in urine and feces. Third, the mean plasma clearance
after i.v. administration was 13.8 mL/min/kg, comparing to a typical hepatic blood flow
of 55.2 mL/min/kg,136 the theoretical hepatic extraction ratio (ER) for this compound
could be estimated as 25% (13.8/55.2). Considering first-pass inactivation alone, this
would suggest that maximum oral bioavailability for KZ-41 could theoretically reach
75% (100%-ER). The actually observed bioavailability of about 100% indicated there
was almost no first-pass inactivation in the intestinal wall and/or the liver. It was
supported by liver microsomal stability study data. Those data suggested that plasma
clearance mainly come from renal and/or other routes.
The plasma protein binding of KZ-41 was moderate and not concentration
dependent over the concentration range of 50 ng/mL to 5000 ng/mL. This finding will be
very useful when choosing dose in animal study, the higher dose will not cause dose
dependent pharmacokinetics problems due to plasma protein binding.
5.4 Conclusion
In summary, KZ-41 was well absorbed with approximately 100% bioavailability
after oral dose in rat. It was not the substrate of bacterial Gluconobacter oxydans. It has
high aqueous solubility and metabolic stability. Its plasma protein binding was moderate.
KZ-41 has good biopharmaceutical and pharmaceutics properties, is ideal for further
development of an orally active anti-inflammatory drug.
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CHAPTER 6. SUMMARY
Quinic acid (QA) esters found in hot water extracts of Uncaria tomentosa (a.k.a.
Cat’s claw) exert anti-inflammatory activity through mechanisms involving inhibition of
the pro-inflammatory transcription factor nuclear factor kappa B (NF-κB). Herein, we
describe the synthesis and biological testing of novel QA derivatives. Inhibition of NFκB was assessed using A549 (Type II alveolar epithelial-like) cells that stably express a
secreted alkaline phosphatase (SEAP) reporter driven by an NF-κB response element.
A549- NF-κB cells were stimulated with TNF-α (10 ng/mL) in the presence or absence of
QA derivative for 18 hours followed by measurement of SEAP activity. Amide
substitution at the carboxylic acid position yielded potent inhibitors of NF-κB. A variety
of modifications to the amide substitution were tolerated with the N-propyl amide
derivative 3 being the most potent. Compound 3 was named as KZ-41. The NF-B
inhibitory potency (IC50) of our most active analog KZ-41 was determined to be
2.83±1.76 M. Further examination of the SAR demonstrated that acetylation of the
hydroxyl groups reduced NF-κB inhibitory activity. QA amide derivatives lacked antioxidant activity and were found to be neither anti-proliferative nor cytotoxic at
concentrations up to 100 M.
We investigated the importance of the hydroxyl groups on the cyclohexane ring
by preparing the dehydroquinate amide analogs. We hypothesized these modifications
will retain anti-inflammatory activity with enhanced resistance to microbial degradation.
The dehydroxyl QA amides 18 and 20 were prepared. They showed NF-B inhibition at
concentration 1 M. The extent of NF-B inhibition was close to positive control drug
dexamethasone. The dehydroxyl QA amide with a double bond 38 was also synthesized.
The QA amide esters 24, 25, 29 and 33 were designed and synthesized to retain antiinflammatory activity with additional antioxidant properties. As expected, compound 25
showed strong anti-oxidant activity. Furthermore, they were hydrolyzed by the microflora,
for an example, 25 was hydrolyzed into SA and 3. Both SA and 3 will not be consumed
by gut bacteria, and are easily absorbed in animal digestive tract. This was done by other
researchers, and not reported here.
To facilitate pre-clinical biopharmaceutic and pharmacokinetic (B/PK) studies of
our lead QA amide analog KZ-41, we developed and validated a novel hydrophilic
interaction liquid chromatography–tandem mass spectrometry (HILIC-MS/MS)
analytical assay. An analog of KZ-41 was used as internal standard (IS). KZ-41 and the
IS were obtained by protein precipitation and separated by HILIC chromatography using
acetonitrile and water. A triple quadrupole mass spectrometer operating in the negative
electrospray ionization mode with multiple reaction monitoring was used to detect KZ-41
and IS transitions of m/z 232 → 178 and 272 → 218 respectively. The lower limit of
quantification (LLOQ) was 0.5 ng/mL in plasma. The method was validated for
selectivity, linearity, accuracy and precision in rat plasma. The ion suppression, recovery
and stability of the analyte in the biological matrix were also tested. The assay developed
is rapid, sensitive and robust enough to support preclinical B/PK studies of KZ-41.
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The study was also conducted to characterize the biopharmaceutics and preclinical pharmacokinetics of the lead QA amide analog, KZ-41. Rats (n=6/group)
received a dose of either an i.v. or p.o. dose (10 mg/kg) of KZ-41. Pharmacokinetic
parameters were determined from concentration - time profiles by non-compartmental
analysis. Bacterial stability study was conducted in cultured bacterial gluconobacter
oxydans. Plasma protein binding and metabolic stability were determined using
equilibrium dialysis and rat liver microsomes respectively. Following i.v. administration,
KZ-41 demonstrated a medium clearance (15.1±4.8 mL/min/kg), medium volume of
distribution (3.3±1.1 L/kg), and a terminal half-life of 2.6±0.4 hrs. KZ-41 was rapidly
absorbed with complete oral bioavailability (F≈1), which was consistent with the fact that
KZ-41 was not susceptible to degradation in bacterial and liver microsomal studies. KZ41 binding to plasma proteins was about 30%. These studies demonstrate that new QA
analog KZ-41 is an orally active anti-inflammatory agent.
In summary, we have discovered a novel series of non-toxic QA amides that
potently inhibit NF-κB activity in TNF-α-stimulated human alveolar Type II-like
epithelial cells (A549). The NF-B inhibitory potency (IC50) of our most active analog
KZ-41 was determined to be 2.83±1.76 M. We have demonstrated that the QA analogs
presented in this work do not exert their activity via anti-oxidant, cytotoxic, or
carrageenan induced paw edema mechanisms. KZ-41 was rapidly absorbed with
complete oral bioavailability (F≈1). It was not the substrate of bacterial Gluconobacter
oxydans. It has high aqueous solubility and metabolic stability. Its plasma protein binding
was moderate. KZ-41 has good biopharmaceutical and pharmaceutics properties, is idea
for further development of an orally active anti-inflammatory drug. Mechanistic studies
and pre-clinical efficacy studies of these newly designed compounds in various in vitro
and in vivo models are on-going by other researchers, and are not reported in this
dissertation.
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